Hypertrophy B-PHE
, I-PHE
Left I-PHE
Ventricular I-PHE

-DOCSTART- O


disperse O
accumulation B-PHE
and O
kill O
worm B-PHE

-DOCSTART- O


Ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine B-PHE
monophosphate I-PHE
dehydrogenase I-PHE
, O
viral O
RNA O
polymerase O
and O
mRNA O
guanylyltransferase O
( O
viral O
) O
and O
can O
be O
incorporated O
into O
RNA O
in O
RNA O
viral O
species O
. O

Sofosbuvir O
is O
a O
nucleotide O
analogue O
inhibitor O
of O
the O
hepatitis O
C O
virus O
polymerase O
which O
is O
a O
RNA-dependent O
RNA O
polymerase O
critical O
for O
the O
viral O
cycle O
. O

Alfa O
interferons O
bind O
to O
specific O
cell-surface O
receptors O
, O
resulting O
in O
the O
transcription O
and O
translation O
of O
genes O
whose O
protein O
products O
mediate O
antiviral B-PHE
, O
antiproliferative B-PHE
, O
anticancer B-PHE
, O
and O
immune-modulating B-PHE
effects O
. O

-DOCSTART- O


jaundice B-PHE
a O
morbid O
condition O
clinically O
characterized O
by O
yellow-brown B-PHE
pigmentation I-PHE
of I-PHE
the I-PHE
skin I-PHE
and I-PHE
sclera I-PHE
and O
dark B-PHE
yellow I-PHE
colored I-PHE
urine I-PHE
, O
and O
classified O
into O
two O
types O
, O
Yang B-PHE
jaundice I-PHE
and O
Eum B-PHE
jaundice I-PHE
; O

one O
of O
the O
five O
types O
of O
jaundice B-PHE
. O

-DOCSTART- O


deafness B-PHE

-DOCSTART- O


Bladder B-PHE
, I-PHE
Neurogenic I-PHE

-DOCSTART- O


alleviate O
edema B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


Its O
biochemical O
mechanism O
of O
action O
is O
unknown O
, O
although O
data O
are O
available O
to O
suggest O
that O
the O
drug O
modifies O
the O
peripheral B-PHE
metabolism I-PHE
of O
steroids O
as O
well O
as O
directly O
suppressing O
the O
adrenal B-PHE
cortex I-PHE
. O

-DOCSTART- O


Kidney B-PHE
disease I-PHE
of O
diabetes B-PHE
type O

-DOCSTART- O


plum-stone B-PHE
syndrome I-PHE
; O
globus B-PHE
hystericus I-PHE
a O
subjective O
sensation O
as O
if O
a O
plum O
pit O
is O
stuck O
in O
the O
throat O
is O
compressed O
. O

-DOCSTART- O


Intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-PHE
effect I-PHE
on O
experimental O
animals O
. O

-DOCSTART- O


Ovarian B-PHE
Cancer I-PHE

-DOCSTART- O


a O
disease O
that O
has O
watery B-PHE
and I-PHE
chronic I-PHE
defecation I-PHE

-DOCSTART- O


Diabetic B-PHE
Neuropathy I-PHE
, O
Painful O

-DOCSTART- O


To O
calm O
asthma B-PHE
, O
dispel O
wind B-PHE
, O
relieve O
pain B-PHE
. O

-DOCSTART- O


Postreperfusion B-PHE
Syndrome I-PHE

-DOCSTART- O


hemiplegia B-PHE
; O

paralysis B-PHE

-DOCSTART- O


Hemodialysis B-PHE

-DOCSTART- O


fever B-PHE
with O
overstrain B-PHE

-DOCSTART- O


Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Rhubarb O
( O
Dahuang O
) O
and O
Dried O
ginger O
( O
Ganjiang O
) O
in O
the O
formula O
Sanwu O
Beiji O
Wan O
. O

-DOCSTART- O


ascites B-PHE
; O
abdominal B-PHE
distention I-PHE
due O
to O
accumulation O
of O
liquid B-PHE

-DOCSTART- O


Analysis O
of O
the O
constituents O
in O
the O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
by O
UPLC/Q-TOF-MS/MS O
. O

-DOCSTART- O


Blood B-PHE
vaculty I-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
amenorrhea B-PHE
, O
postpartum B-PHE
vacuity I-PHE
weakness I-PHE
, O
aching B-PHE
in I-PHE
lumbus I-PHE
and I-PHE
legs I-PHE
, O
fracture B-PHE
due O
to O
knocks O
and O
falls O
. O

-DOCSTART- O


eliminate O
vexation B-PHE
and O
thirst B-PHE

-DOCSTART- O


hypochondriac B-PHE
pain I-PHE

-DOCSTART- O


invigorate O
waist B-PHE
and O
limbs B-PHE

-DOCSTART- O


ISS O
1018 O
signals O
through O
Toll-like O
receptor O
9 O
( O
TLR9 O
) O
to O
induce O
the O
production O
of O
immunoglobulin O
by O
B O
cells O
and O
interferon O
( O
IFN O
) O
#NAME? O
, O
IFN-beta B-PHE
, O
interleukin-12 B-PHE
( O
IL-12 B-PHE
) O
, O
and O
tumor B-PHE
necrosis I-PHE
factor I-PHE
- I-PHE
alpha I-PHE
( O
TNF-alpha B-PHE
) O
by O
plasmacytoid O
dendritic O
cells O
( O
pDC O
) O
. O

pDC O
and O
IFN-alpha O
and O
#NAME? O
then O
induce O
natural B-PHE
killer I-PHE
( O
NK B-PHE
) O
cell B-PHE
proliferation I-PHE
, O
NK B-PHE
cell I-PHE
production I-PHE
of O
IFN-gamma B-PHE
, O
and O
NK B-PHE
cell-mediated I-PHE
cytotoxicity I-PHE
. O

Secreted O
IFNs O
also O
stimulate O
bystander O
T B-PHE
cell I-PHE
activation I-PHE
and O
differentiation O
of O
naive O
CD4+ O
T O
cells O
into O
T-helper O
1 O
cells O
on O
specific O
antigen O
challenge O
. O

-DOCSTART- O


Diabetes B-PHE
Mellitus I-PHE
, I-PHE
Type I-PHE
2 I-PHE

-DOCSTART- O


clear O
the O
lung B-PHE
and O
discharge O
fire B-PHE

-DOCSTART- O


Pregnancy B-PHE

-DOCSTART- O


promote O
the O
stomach B-PHE
and O
disperse O
food O

-DOCSTART- O


pain B-PHE
in O
the O
supraorbital O
bone O

-DOCSTART- O


Gabapentin O
interacts O
with O
cortical B-PHE
neurons I-PHE
at O
auxillary O
subunits O
of O
voltage-sensitive O
calcium O
channels O
and O
increases O
the O
synaptic B-PHE
concentration I-PHE
of I-PHE
GABA I-PHE
, O
enhances O
GABA B-PHE
responses I-PHE
at O
non-synaptic O
sites O
in O
neuronal O
tissues O
, O
and O
reduces O
the O
release O
of O
mono-amine B-PHE
neurotransmitters I-PHE
. O

Duloxetine O
selectively O
prevents O
the O
reuptake B-PHE
of I-PHE
5-HT I-PHE
and I-PHE
NE I-PHE
via O
transporter O
complexes O
on O
the O
pre-synaptic B-PHE
membrane I-PHE
, O
thereby O
increasing O
the O
level O
of O
these O
neurotransmitters B-PHE
within O
the O
synaptic O
cleft O
. O

-DOCSTART- O


an O
illness O
in O
which O
phlegm B-PHE
formed O
on O
chest O

-DOCSTART- O


Psoriatic B-PHE
Arthritis I-PHE

-DOCSTART- O


invigorate O
the O
spleen B-PHE
and O
resolve O
accumulation O

-DOCSTART- O


BACKGROUND O
_ O
AIMS O
: O
Chemotherapy O
with O
an O
anticancer O
agent O
generally O
causes O
gastrointestinal B-PHE
tract I-PHE
disorders I-PHE
such O
as O
vomiting B-PHE
and O
anorexia B-PHE
, O
but O
the O
mechanism O
remains O
unclear O
. O

Rikkunshito O
, O
a O
kampo O
preparation O
, O
is O
known O
to O
alleviate O
such O
adverse O
reactions O
. O

In O
this O
study O
, O
we O
attempted O
to O
clarify O
the O
mechanism O
. O

METHODS O
: O
We O
investigated O
the O
decreases O
of O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
and O
food O
intake O
caused O
by O
cisplatin O
, O
serotonin B-PHE
( O
5-HT B-PHE
) O
, O
5-HT O
agonists O
, O
and O
vagotomy O
as O
well O
as O
the O
decrease-suppressing O
effects O
of O
rikkunshito O
and O
5-HT O
antagonists O
. O

In O
addition O
, O
binding O
affinities O
of O
rikkunshito O
components O
were O
determined O
in O
receptor-binding O
assays O
using O
5-HT2B O
and O
5-HT2C O
receptors O
. O

RESULTS O
: O
Cisplatin O
, O
5-HT B-PHE
, O
BW723C86 O
( O
5-HT2B-receptor O
agonist O
) O
, O
and O
m-chlorophenylpiperazine O
HCl O
( O
5-HT2C O
agonist O
) O
markedly O
decreased O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
levels I-PHE
, O
although O
5-HT3 O
and O
5-HT4 O
agonists O
had O
no O
effect O
. O

In O
contrast O
, O
5-HT2B O
and O
5-HT2C O
antagonists O
suppressed O
the O
cisplatin-induced O
decrease O
of O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
and O
food O
intake O
. O

Administration O
of O
rat O
ghrelin B-PHE
improved O
the O
cisplatin-induced O
decrease O
in O
food O
intake O
. O

Vagotomy O
decreased O
the O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
, O
which O
was O
decreased O
further O
by O
cisplatin O
. O

Rikkunshito O
suppressed O
such O
cisplatin-induced O
decreases O
of O
plasma B-PHE
acylated- I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
and O
food O
intake O
. O

The O
suppressive O
effect O
of O
rikkunshito O
was O
blocked O
by O
a O
ghrelin O
antagonist O
. O

Components O
of O
rikkunshito O
, O
3,3',4',5,6,7,8-heptamethoxyflavone O
, O
hesperidin O
, O
and O
iso-liquiritigenin O
showed O
a O
5-HT2B-antagonistic O
effect O
in O
vitro O
, O
and O
oral O
administration O
of O
rikkunshito O
suppressed O
the O
cisplatin-induced O
decrease O
in O
the O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
. O

CONCLUSIONS O
: O
The O
cisplatin-induced O
decreases O
of O
the O
plasma B-PHE
acylated I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
and O
food O
intake O
are O
mediated O
by O
5-HT2B/2C O
receptors O
and O
suppressed O
by O
flavonoids O
in O
rikkunshito O
. O

-DOCSTART- O


The O
symptomatic O
relief O
of O
cough B-PHE
. O

-DOCSTART- O


Its O
alcoholic O
extract O
relaxes O
the O
spasm B-PHE
of I-PHE
smooth I-PHE
muscles I-PHE
of O
gastrointestine O
, O
gallbladder O
and O
bronchus. O
. O

-DOCSTART- O


Hwansodan O
has O
been O
used O
as O
a O
prescription O
for O
senile B-PHE
and O
vascular B-PHE
dementia I-PHE
in O
Oriental O
medicine O
. O

We O
investigated O
the O
neuroprotective B-PHE
effects I-PHE
of O
Hwansodan O
water O
extract O
on O
the O
apoptotic B-PHE
death I-PHE
of O
PC12 O
cells O
by O
serum O
deprivation O
. O

Hwansodan O
significantly O
rescued O
PC12 O
cells O
from O
apoptotic B-PHE
death I-PHE
by O
serum O
deprivation O
in O
a O
dose-dependent O
manner O
. O

The O
nuclear O
staining O
of O
PC12 O
cells O
clearly O
showed O
that O
Hwansodan O
attenuated O
nuclear O
condensation O
and O
fragmentation O
, O
which O
represents O
typical O
neuronal O
apoptotic O
characteristics O
. O

Hwansodan O
also O
prevents O
DNA O
fragmentation O
and O
caspase-3-like O
protease O
activation O
in O
serum-deprived O
PC12 O
cells O
and O
induces O
the O
tyrosine O
phosphorylation O
of O
proteins O
around O
44 O
kDa O
, O
which O
was O
identified O
as O
ERK1 O
with O
electrophoretic O
gel O
mobility O
shift O
by O
Western O
blot O
. O

In O
addition O
, O
MEK O
inhibitor O
PD98059 O
and O
Ras O
inactivator O
, O
alpha-hydroxyfarnesylphosphonic O
acid O
and O
mevastatin O
, O
attenuated O
the O
neuroprotective O
effects O
of O
Hwansodan O
in O
serum-deprived O
PC12 O
cells O
. O

These O
results O
indicate O
that O
Ras O
/ O
MEK O
/ O
ERK O
signaling O
pathway O
plays O
a O
role O
in O
neuroprotective B-PHE
effects I-PHE
of O
Hwansodan O
in O
serum-deprived O
PC12 O
cells O
. O

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility B-PHE
. O

-DOCSTART- O


asthma B-PHE

-DOCSTART- O


1 O
Treatment O
of O
rheumatism B-PHE
, O
trauma B-PHE
, O
headache B-PHE
, O
and O
other O
pains B-PHE
. O

Recently O
, O
also O
used O
for O
abdominal B-PHE
and I-PHE
biliary I-PHE
colics I-PHE
, O
and O
trigeminal B-PHE
neuralgia I-PHE
. O

2 O
. O
Treatment O
of O
bronchial B-PHE
asthma I-PHE
and O
asthmatic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Hernioplasty O

-DOCSTART- O


infantile B-PHE
malnutrition I-PHE
an O
infantile B-PHE
disease I-PHE
due O
to O
digestive B-PHE
disturbance I-PHE
or O
intestinal B-PHE
parasites I-PHE
with O
symptoms O
of O
wasting O
, O
pallor B-PHE
or O
sallowness B-PHE
, O
potbelly B-PHE
, O
and O
chronic B-PHE
diarrhea I-PHE
. O

-DOCSTART- O


To O
benefit O
qi O
; O
To O
soothe O
stomach B-PHE
; O
To O
reduce O
lump B-PHE
; O
To O
stop O
vomiting B-PHE

-DOCSTART- O


soothe O
the O
sinews B-PHE
and O
invigorate O
the O
network B-PHE
vessels I-PHE

-DOCSTART- O


thicken O
the O
intestine B-PHE
and O
stomach B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
feeling O
like O
vomiting B-PHE
caused O
by O
ascending O
stomach B-PHE
Gi O
. O

-DOCSTART- O


Its O
chief O
component O
is O
berberine O
. O

Possessing O
broad-spectrum O
antibacterial B-PHE
and O
antiprotozoal B-PHE
effects O
. O

Intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-PHE
effect O
on O
experimental O
animals O
. O

Small O
dosage O
of O
berberine O
enhances O
the O
action O
of O
acetylcholine O
on O
animals' O
hearts B-PHE
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

Relaxing O
the O
smooth B-PHE
muscles I-PHE
of O
blood O
vessels O
and O
stimulating O
those O
of O
uterus B-PHE
, O
urinary B-PHE
bladderl I-PHE
bronchus I-PHE
and O
gastrointestines B-PHE
. O

Promoting O
bile B-PHE
secretion I-PHE
. O

Berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic O
cancer B-PHE
and O
lymphoma B-PHE
. O

-DOCSTART- O


Used O
in O
surgical O
procedures O
where O
a O
rapid O
onset O
and O
brief O
duration O
of O
muscle B-PHE
relaxation I-PHE
is O
needed O
( O
includes O
intubation O
, O
endoscopies O
, O
and O
ECT O
) O

-DOCSTART- O


Keishibukuryogan O
ameliorates O
glucose B-PHE
intolerance I-PHE
and O
hyperlipidemia B-PHE
in O
Otsuka O
Long-Evans O
Tokushima O
Fatty O
( O
OLETF O
) O
rats O
. O

-DOCSTART- O


relieve O
lactation O
and O
disperse O
edema B-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
benign B-PHE
prostatic I-PHE
hyperplasia I-PHE
. O

-DOCSTART- O


fever B-PHE
with O
affection O
by O
cold B-PHE

-DOCSTART- O


Myelodysplastic B-PHE
Syndrome I-PHE

-DOCSTART- O


Portal B-PHE
Hypertension I-PHE

-DOCSTART- O


May O
be O
used O
to O
treat O
primary O
, O
secondary O
or O
tertiary O
hypothyroidism B-PHE
. O

May O
also O
be O
used O
to O
suppress O
thyroid B-PHE
stimulating O
hormone O
( O
TSH O
) O
secretion O
in O
patients O
with O
simple O
( O
nontoxic O
) O
goiter B-PHE
, O
subacute O
or O
chronic O
lymphocytic B-PHE
thyroiditis I-PHE
multinodular I-PHE
goiter I-PHE
, O
and O
in O
the O
management O
of O
thyroid B-PHE
cancer I-PHE
. O

May O
be O
used O
in O
conjunction O
with O
other O
antithyroid O
agents O
to O
treat O
thyrotoxicosis B-PHE
to O
prevent O
goitrogenesis O
and O
hypothyroidism B-PHE
. O

May O
also O
be O
used O
for O
differential O
diagnosis O
of O
suspected O
mild O
hyperthyroidism B-PHE
or O
thyroid B-PHE
gland I-PHE
autonomy O
. O

-DOCSTART- O


hasten O
delivery O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
regulate O
menstruation B-PHE
. O

-DOCSTART- O


consumption B-PHE
; O

deficiency B-PHE
syndrome I-PHE
; O

disease O
due O
to O
asthenia B-PHE
of O
the O
viscera O

-DOCSTART- O


1 O
For O
cases O
attributive O
to O
deficiency B-PHE
and O
collapse O
of O
vital O
energy O
and O
downward O
flowing O
of O
essential O
substance,which O
manifest O
as O
prolonged O
discharge O
of O
rice-water O
like O
urine B-PHE
, O
pale B-PHE
complexion I-PHE
, O
fatigue B-PHE
, O
pale B-PHE
tongue I-PHE
and O
feeble B-PHE
pulse I-PHE
, O
add O
Fructus O
Corni O
to O
keep O
t O

-DOCSTART- O


Treatment O
haematemesis B-PHE
, O
epistaxis B-PHE
and O
hematuria B-PHE
due O
to O
heat B-PHE
in O
the O
blood B-PHE
, O
febrile B-PHE
diseases I-PHE
with O
thirst B-PHE
, O
jaundice B-PHE
, O
urinary B-PHE
infection I-PHE
with O
difficult O
painful B-PHE
urination I-PHE
, O
edema B-PHE
in O
acute B-PHE
nephritis I-PHE
. O

-DOCSTART- O


Lopinavir O
inhibits O
HIV B-PHE
protease I-PHE
. O

Ritonavir O
inhibits O
the O
CYP3A O
mediated O
metabolism B-PHE
of I-PHE
lopinavir I-PHE
, O
thereby O
providing O
increased O
plasma O
level O
of O
lopinavir O
. O

-DOCSTART- O


vertigo B-PHE
due O
to O
wind-phlegm B-PHE

-DOCSTART- O


In O
order O
to O
better O
understand O
the O
characteristics O
of O
atmospheric O
carbonaceous O
aerosol O
at O
a O
background O
site O
in O
Northeast O
Asia O
, O
semicontinuous O
organic O
carbon O
( O
OC O
) O
and O
elemental O
carbon O
( O
EC O
) O
, O
and O
time-resolved O
water-soluble O
organic O
carbon O
( O
WSOC O
) O
were O
measured O
by O
a O
Sunset O
OC O
/ O
EC O
and O
a O
PILS-TOC O
( O
particle-into-liquid O
sampler O
coupled O
with O
an O
online O
total O
organic O
carbon O
) O
analyzer O
, O
respectively O
, O
at O
the O
Gosan O
supersite O
on O
Jeju O
Island O
, O
Korea O
, O
in O
the O
summer O
( O
May O
42914 O
17 O
) O
and O
fall O
( O
August O
43002 O
30 O
) O
of O
2009 O
. O

Hourly O
average O
OC O
concentration O
varied O
in O
the O
range O
of O
approximately O
0.87-28.38 O
microgC O
m-3 O
, O
with O
a O
mean O
of O
4.07+/- O
2.6 O
microgC O
m-3 O
, O
while O
the O
hourly O
average O
EC O
concentration O
ranged O
approximately O
from O
0.04 O
to O
8.19 O
. O

microgC O
m-3 O
, O
with O
a O
mean O
of O
1.35 O
+/- O
0.71 O
microgC O
m-3 O
, O
from O
May O
28 O
to O
June O
17 O
, O
2009 O
. O
During O
the O
fall O
season O
, O
OC O
varied O
in O
the O
approximate O
range O
0.9-9.6 O
microgC O
m-3 O
, O
with O
a O
mean O
of O
2.3 O
+/-0.80 O
microgC O
m-3 O
, O
whereas O
EC O
ranged O
approximately O
from O
0.01 O
to O
5.4 O
microgC O
m-3 O
, O
with O
a O
mean O
of O
0.66 O
+/- O
0.38 O
microgC O
m-3 O
. O

Average O
contributions O
of O
EC O
to O
TC O
and O
WSOC O
to O
OC O
were O
0.26 O
+/- O
0.097 O
and O
0.206 O
+/-7.4% O
, O
and O
0.376 O
+/- O
0.235 O
and O
0.572 O
+/- O
0.222 O
during O
summer O
and O
fall O
seasons O
, O
respectively O
. O

As O
expected O
, O
clear O
diurnal O
variation O
of O
WSOC/OC O
was O
found O
in O
summer O
, O
varying O
from O
0.22 O
during O
the O
nighttime O
up O
to O
0.72 O
during O
the O
daytime O
, O
mainly O
due O
to O
the O
photo-oxidation O
process O
. O

In O
order O
to O
investigate O
the O
effect O
of O
air O
mass O
pathway O
on O
the O
characteristics O
of O
carbonaceous O
aerosol O
, O
5-day O
back-trajectory O
analysis O
was O
conducted O
using O
the O
HYSPLIT O
model O
. O

The O
air O
mass O
pathways O
were O
classified O
into O
four O
types O
: O
Continental O
( O
CC O
) O
, O
Marine O
( O
M O
) O
, O
East O
Sea O
( O
ES O
) O
and O
Korean O
Peninsula O
( O
KP O
) O
. O

The O
highest O
OC/EC O
ratio O
of O
3.63 O
was O
observed O
when O
air O
mass O
originated O
from O
the O
Continental O
area O
( O
CC O
) O
. O

The O
lowest O
OC/EC O
ratio O
of O
0.79 O
was O
measured O
when O
air O
mass O
originated O
from O
the O
Marine O
area O
( O
M O
) O
. O

A O
high O
OC O
concentration O
was O
occasionally O
observed O
at O
Gosan O
due O
to O
local O
biomass O
burning O
activities O
. O

The O
contribution O
of O
secondary O
OC O
to O
total O
OC O
varied O
approximately O
between O
0.084 O
and O
0.322 O
and O
depended O
on O
air O
mass O
type O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
move O
qi O
and O
quicken O
blood B-PHE
. O

-DOCSTART- O


illness B-PHE
that O
occurs O
on O
teeth O

-DOCSTART- O


Muscle B-PHE
Fatigue I-PHE

-DOCSTART- O


anticancer B-PHE

-DOCSTART- O


repel O
all O
malign O
sore B-PHE

-DOCSTART- O


1 O
Flavonoid O
glycoside O
, O
one O
of O
its O
components O
, O
increases O
coronary B-PHE
flow I-PHE
, O
reduces O
myocardial B-PHE
oxygen I-PHE
consumption I-PHE
and O
lowers O
arterial B-PHE
pressure I-PHE
. O

2 O
. O
Cardiotonic O
on O
frogs' O
hearts O
in O
vitro O
; O
low O
concentration O
of O
its O
extract O
exerts O
a O
vasoconstrictive O
effect O
on O
the O
vessels O
of O
frogs' O
leg O
and O
high O
concentration O
, O
vasodilative O

3 O
. O
Its O
liquid O
extract O
shortens B-PHE
clotting I-PHE
time I-PHE
and O
exerts O
hemostatic B-PHE
effect I-PHE
in O
rabbit O
. O

-DOCSTART- O


affection O
by O
cold B-PHE
1 O
common O
cold B-PHE
2 O
influenza B-PHE

-DOCSTART- O


Complications B-PHE
due O
to O
blood B-PHE
stagnation I-PHE

-DOCSTART- O


settle O
the O
pain B-PHE

-DOCSTART- O


inability B-PHE
to O
turn O
over O

-DOCSTART- O


headache B-PHE

-DOCSTART- O


Treatment O
of O
endemic B-PHE
goiter I-PHE
, O
hyperthyroidism B-PHE
, O
whooping B-PHE
cough I-PHE
, O
cough B-PHE
of O
lung-heat O
type O
, O
thyroid B-PHE
adenoma I-PHE
, O
thyroid B-PHE
cancer I-PHE
, O
tumour B-PHE
of O
digestive O
tract O
, O
lung B-PHE
and I-PHE
mammary I-PHE
cancer I-PHE
, O
etc O
. O

-DOCSTART- O


stop O
bleeding B-PHE

-DOCSTART- O


HIV-1 B-PHE
Infection I-PHE

-DOCSTART- O


Possessing O
broad-spectrum O
antibacterial B-PHE
and I-PHE
antiprotozoal I-PHE
effects I-PHE
. O

-DOCSTART- O


severe O
palpitation I-PHE
; O

continuous O
violent O
palpitation B-PHE

-DOCSTART- O


impotence B-PHE

-DOCSTART- O


Unspecified O
Childhood O
Solid B-PHE
Tumor I-PHE
, O
Protocol O
Specific O

-DOCSTART- O


strengthen O
tooth B-PHE

-DOCSTART- O


stop O
bleeding B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


To O
remove O
toxic B-PHE
heat I-PHE
, O
to O
soothe O
the O
sore B-PHE
throat I-PHE
, O
to O
resolve O
phlegm B-PHE
, O
and O
to O
relieve O
dysuria B-PHE
. O

-DOCSTART- O


Polysaccharide-Containing O
Macromolecules O
in O
a O
Kampo O
( O
Traditional O
Japanese O
Herbal O
) O
Medicine O
, O
Hochuekkito O
: O
Dual O
Active O
Ingredients O
for O
Modulation O
of O
Immune O
Functions O
on O
Intestinal B-PHE
Peyer's I-PHE
Patches I-PHE
and O
Epithelial B-PHE
cells I-PHE
. O

-DOCSTART- O


cool O
blood B-PHE
and O
stop O
dysentery B-PHE

-DOCSTART- O


Promethazine O
hydrochloride O
selectively O
blocks O
peripheral O
H1 O
receptors O
thereby O
diminishing O
the O
effects B-PHE
of I-PHE
histamine I-PHE
on O
effector O
cells O
. O

-DOCSTART- O


difficulty B-PHE
in I-PHE
urination I-PHE
and I-PHE
defecation I-PHE
; O
constipation B-PHE
and O
ischuria B-PHE

-DOCSTART- O


difficulty B-PHE
in I-PHE
urination I-PHE

-DOCSTART- O


reinforce O
bone B-PHE
fracture I-PHE

-DOCSTART- O


Healthy B-PHE

-DOCSTART- O


The O
Chinese O
herb O
modified O
Yi O
Guan O
Jian O
( O
mYGJ O
) O
is O
an O
effective O
regimen O
that O
is O
usually O
used O
in O
outpatients O
with O
chronic B-PHE
liver I-PHE
diseases I-PHE
such O
as O
fibrosis B-PHE
and O
cirrhosis B-PHE
. O

However O
, O
the O
mechanism O
for O
the O
action O
of O
mYGJ O
on O
liver B-PHE
fibrosis I-PHE
is O
not O
yet O
clear O
. O

In O
this O
study O
, O
we O
found O
that O
mYGJ O
induced O
hepatic B-PHE
stellate I-PHE
cells I-PHE
( O
HSCs B-PHE
) O
apoptosis O
concomitant O
with O
the O
downregulation O
of O
Bcl-2 B-PHE
expression I-PHE
and O
slight O
elevation O
of O
Bax B-PHE
level I-PHE
. O

Moreover O
, O
the O
reactive O
oxygen O
species O
( O
ROS O
) O
were O
generated O
in O
the O
early O
stages O
of O
mYGJ-induced B-PHE
HSCs I-PHE
apoptosis I-PHE
to O
facilitate O
calcium O
and O
cytochrome O
c O
release O
from O
the O
mitochondria O
to O
cytosol O
. O

Subsequently O
, O
caspase B-PHE
9 I-PHE
and O
caspase B-PHE
3 I-PHE
were O
activated O
. O

Furthermore O
, O
the O
activation O
of O
ER O
stress-associated O
caspase B-PHE
12 I-PHE
in O
HSCs B-PHE
was O
also O
evaluated O
. O

Together O
, O
we O
report O
the O
first O
evidence-based O
study O
to O
demonstrate O
that O
mYGJ O
decoction O
induces O
HSCs B-PHE
apoptosis O
through O
ROS O
accumulation O
and O
the O
intrinsic O
apoptosis O
pathway O
. O

These O
findings O
provide O
rationale O
for O
further O
clinical O
investigation O
of O
traditional O
Chinese O
medicine O
recipes O
against O
liver B-PHE
fibrosis I-PHE
. O

-DOCSTART- O


Diagnostic O
agent O
for O
radionuclide O
myocardial O
perfusion O
imaging O
( O
MPI O
) O

-DOCSTART- O


Otitis B-PHE
Media I-PHE

-DOCSTART- O


Dilating O
the O
coronary B-PHE
artery I-PHE
and O
blood B-PHE
vessels I-PHE
of O
hind O
legs O
in O
dogs O
. O

Lowering O
blood B-PHE
pressure I-PHE
transiently O
. O

Inhibiting O
the O
intestines B-PHE
in O
rabbits O
in O
vitro O
. O

Its O
component O
paeoniflorin O
inhibits O
the O
central B-PHE
nervous I-PHE
systems I-PHE
. O

-DOCSTART- O


Hydrocortisone O
binds O
to O
the O
cytosolic O
glucocorticoid O
receptor O
and O
promotes O
protein B-PHE
catabolism I-PHE
, O
gluconeogenesis B-PHE
, O
capillary B-PHE
wall I-PHE
stability I-PHE
, O
renal B-PHE
excretion I-PHE
of I-PHE
calcium I-PHE
, O
and O
suppresses O
immune B-PHE
and I-PHE
inflammatory I-PHE
responses I-PHE
. O

Polymyxin O
B O
sulfate O
interacts O
with O
the O
lipopolysaccharide B-PHE
of O
the O
cytoplasmic O
outer O
membrane O
of O
Gram-negative O
bacteria O
, O
altering O
membrane B-PHE
permeability I-PHE
and O
causing O
cell B-PHE
death I-PHE
. O

Chloramphenicol O
reversibly O
binds O
to O
the O
L16 O
protein O
of O
the O
50S O
subunit O
of O
bacterial O
ribosomes O
, O
thus O
inhibits O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


Its O
component O
oleanolic O
acid O
can O
prevent O
and O
relieve O
cyclophosphamide-induced B-PHE
leukocytopenia I-PHE
in O
mice O
. O

Enhancing O
the O
anoxia B-PHE
tolerance I-PHE
of O
mice O
under O
atmospheric O
pressure O
. O

Increasing O
coronary B-PHE
flow I-PHE
in O
rabbits O
in O
vitro O
. O

Relaxing O
adrenaline-induced B-PHE
vasocontricyion I-PHE
in O
rabbits O
in O
vitro O
. O

Lowering O
the O
level O
of O
blood B-PHE
lipid I-PHE
. O

-DOCSTART- O


reinforce O
marrow B-PHE

-DOCSTART- O


deficiency B-PHE
and I-PHE
cold I-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
stomach I-PHE
; O
hypofunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE
with O
cold B-PHE
manifestations O

-DOCSTART- O


Benzodiazepines O
, O
in O
this O
way O
, O
block O
the O
cortical B-PHE
and I-PHE
limbic I-PHE
arousal I-PHE
that O
occurs O
following O
stimulation O
of O
the O
reticular O
pathways O
. O

-DOCSTART- O


red B-PHE
face I-PHE

-DOCSTART- O


all O
kinds O
of O
malignant B-PHE
furuncle I-PHE

-DOCSTART- O


declination O
of O
the O
fire O
of O
the O
vital O
gate O
dysfunction O
of O
reproduction O
due O
to O
insufficiency O
of O
the O
kidney-yang O
. O

-DOCSTART- O


precipitation B-PHE
of I-PHE
blood I-PHE
during O
pregnancy B-PHE

-DOCSTART- O


distention B-PHE
and I-PHE
pain I-PHE
in I-PHE
chest I-PHE
and I-PHE
abdomen I-PHE
with O
driving O
up O
Qi O

-DOCSTART- O


boil B-PHE
in O
the O
throat O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
hepatitis B-PHE
( O
viral B-PHE
, I-PHE
B I-PHE
) O
. O

-DOCSTART- O


Asthma B-PHE
, O
chronic B-PHE
bronchitis I-PHE
, O
stomachache B-PHE
, O
wind-damp B-PHE
pain I-PHE
, O
scrofula B-PHE
, O
cold B-PHE
suppurative I-PHE
sore I-PHE
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Diabetes B-PHE
, O
annoyment O
, O
thirst B-PHE
, O
easy O
to O
get O
hungry B-PHE
, O
tiredness B-PHE
and O
underweight B-PHE
, O
dry B-PHE
mouth I-PHE
and I-PHE
throat I-PHE
, O
short B-PHE
breath I-PHE
and O
nervousness B-PHE
, O
sweating B-PHE
, O
dry B-PHE
stool I-PHE
, O
red B-PHE
tong I-PHE
and O
lack B-PHE
of I-PHE
saliva I-PHE
, O
weak O
and O
frequent B-PHE
pulse I-PHE

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Overall O
CVD B-PHE
, O
Other O
system B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


Ceftazidime O
inhibits O
the O
bacteria B-PHE
cell I-PHE
wall I-PHE
synthesis I-PHE
via O
affinity O
for O
penicillin B-PHE
- I-PHE
binding I-PHE
proteins I-PHE
( O
PBPs B-PHE
) O
. O

The O
reduced O
metronidazole O
then O
covalently O
binds O
to O
DNA O
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial B-PHE
nucleic I-PHE
acid I-PHE
synthesis I-PHE
and O
resulting O
in O
bacterial B-PHE
cell I-PHE
death I-PHE
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Woman O
, O
Endocrine B-PHE
system I-PHE
, O
Lipid B-PHE
profile I-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
General O
woman O

-DOCSTART- O


Secretin O
binds O
to O
the O
secretin O
receptor O
found O
on O
the O
lining O
of O
S O
cells O
in O
the O
duodenum O
and O
G O
cells O
in O
the O
stomach O
. O

Binding O
leads O
to O
the O
secrection O
of O
bicarbonate O
or O
the O
reduction O
of O
the O
secretion B-PHE
of I-PHE
gastrin I-PHE
. O

Properly O
functioning O
organs O
( O
duodenum B-PHE
, O
pancreas B-PHE
and O
stomach B-PHE
) O
should O
be O
responsive O
to O
this O
hormone O

-DOCSTART- O


Cough B-PHE
and O
shortness B-PHE
of I-PHE
breath I-PHE
, O
wind-damp B-PHE
impediment I-PHE
pain I-PHE
, O
itchy B-PHE
skin I-PHE
, O
innominate O
toxin B-PHE
swelling I-PHE
. O

-DOCSTART- O


For O
eliminating O
toxic B-PHE
materials I-PHE
, O
dissolving O
rottenness B-PHE
and O
growing O
new O
muscles B-PHE

-DOCSTART- O


The O
mechanism O
of O
action O
and O
receptor O
for O
PCK3145 O
suggests O
PCK3145 O
to O
be O
a O
signal O
transduction O
inhibitor O
with O
multiple O
ways O
( O
apoptosis B-PHE
, O
anti-angiogenesis B-PHE
and O
anti-metastasis B-PHE
) O
to O
restrict O
disease B-PHE
development I-PHE
. O

-DOCSTART- O


menstrual B-PHE
abdominal I-PHE
pain I-PHE

-DOCSTART- O


Treatment O
of O
arthralgia B-PHE
with O
weakness B-PHE
of O
the O
loins O
and O
knees O
, O
excessive B-PHE
menstrual I-PHE
flow I-PHE
, O
chronic B-PHE
phthisical I-PHE
cough I-PHE
. O

-DOCSTART- O


For O
the O
treatment O
of O
rheumatoid B-PHE
arthritis I-PHE
( O
RA B-PHE
) O
. O

-DOCSTART- O


Fever B-PHE
, O
Sweats B-PHE
, O
and O
Hot B-PHE
Flashes I-PHE

-DOCSTART- O


Damp-heat B-PHE
diarrhea I-PHE
, O
vaginal B-PHE
discharge I-PHE
, O
hemorrhoids B-PHE
, O
pain B-PHE
from O
swollen O
welling O
abscess B-PHE
, O
scrofula B-PHE
. O

-DOCSTART- O


1 O
Inhibiting O
sarcoma180 B-PHE
and O
cervix B-PHE
carcinoma14 I-PHE
in O
mice O
and O
L16 O
cells O
isolated O
from O
human O
liver B-PHE
cancer I-PHE
. O

2 O
. O
Promoting O
the O
adrenocortical B-PHE
function I-PHE
in O
mice O
. O

3 O
. O
Promoting O
metabolism B-PHE
and O
reticuloendothelial B-PHE
function I-PHE
. O

-DOCSTART- O


Vaccination O
of O
humans O
with O
CYT006-AngQb O
has O
been O
shown O
to O
induce O
angiotensin B-PHE
II I-PHE
specific O
antibodies O
that O
should O
inhibit O
binding O
of O
angiotensin B-PHE
II I-PHE
to O
its O
receptors O
and O
thus O
reduce O
the O
narrowing B-PHE
of I-PHE
blood I-PHE
vessels I-PHE
. O

-DOCSTART- O


warm O
the O
middle O
and O
disperse O
cold B-PHE

-DOCSTART- O


Mycophenolate O
stops O
T-cell B-PHE
and I-PHE
B-cell I-PHE
proliferation I-PHE
through O
selective O
inhibition O
of O
the O
de O
novo O
pathway O
of O
purine B-PHE
biosynthesis I-PHE
. O

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
regulate O
menstruation B-PHE
, O
dissipate O
stasis B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


For O
relieving O
exterior B-PHE
syndrome I-PHE

-DOCSTART- O


anhidrosis B-PHE
and O
aversion B-PHE
to I-PHE
cold I-PHE

-DOCSTART- O


To O
Disperse O
the O
stagnated O
liver-qi O
, O
to O
remove O
heat B-PHE
, O
invigorate O
the O
spleen B-PHE
and O
nourishing O
blood B-PHE
. O

-DOCSTART- O


Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
, O
Protective O
immunity B-PHE
, O
Overall O
CVD B-PHE

-DOCSTART- O


dispel O
stasis B-PHE

-DOCSTART- O


For O
activating O
blood B-PHE
and O
reducing O
pain B-PHE
. O

-DOCSTART- O


abdominal B-PHE
distension I-PHE
; O
abdominal B-PHE
fullness I-PHE

-DOCSTART- O


nfantile B-PHE
convulsive I-PHE
seizure I-PHE
due O
to O
fright O

-DOCSTART- O


damage B-PHE
of I-PHE
kidney I-PHE

-DOCSTART- O


Urologic B-PHE
Diseases I-PHE

-DOCSTART- O


Treatment O
of O
stagnation O
of O
qi O
of O
the O
liver B-PHE
and O
stomach B-PHE
marked O
by O
distension B-PHE
and O
pain B-PHE
in O
the O
chest O
and O
hypochondriac O
regions O
, O
stuffiness B-PHE
feeling O
in O
the O
stomach O
, O
anorexia B-PHE
and O
vomiting B-PHE
. O

-DOCSTART- O


have O
no B-PHE
menstruation I-PHE
due O
to O
static B-PHE
blood I-PHE
. O

-DOCSTART- O


In O
countries O
with O
high O
rates O
of O
hepatitis B-PHE
B I-PHE
infection I-PHE
, O
vaccination O
of O
newborns O
has O
not O
only O
reduced O
the O
risk O
of O
infection B-PHE
, O
but O
has O
also O
led O
to O
marked O
reduction O
in O
liver B-PHE
cancer I-PHE
. O

-DOCSTART- O


Gastric B-PHE
Cancer I-PHE

-DOCSTART- O


rigidity B-PHE
of O
the O
limbs O
; O

contracture B-PHE
; O

subjective B-PHE
sensation I-PHE
of O
contraction O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Body B-PHE
weight I-PHE

-DOCSTART- O


Pseudoephedrine O
relaxes O
bronchial B-PHE
smooth I-PHE
muscle I-PHE
by O
stimulating O
beta2-adrenergic O
receptors O
. O

Hydrocodone O
exerts O
its O
analgesic O
activity O
by O
binding O
to O
the O
mu-receptors O
in O
the O
central B-PHE
nervous I-PHE
system I-PHE
( O
CNS B-PHE
) O
, O
thereby O
mimicking O
the O
effects O
of O
endogenous O
opioids O
. O

-DOCSTART- O


move O
blood B-PHE

-DOCSTART- O


white B-PHE
vaginal I-PHE
discharge I-PHE
; O
leukorrhea B-PHE

-DOCSTART- O


Blood B-PHE
stasis I-PHE
in O
the O
hypochondriac O
region O
due O
to O
traumatic B-PHE
injury I-PHE
characterised O
by O
hypochondriac B-PHE
pain I-PHE
. O

Traumatic O
swelling O
pain B-PHE
, O
intercostal B-PHE
neuralgia I-PHE
, O
costal B-PHE
chrondritis I-PHE
marked O
by O
accumulation O
of O
blood B-PHE
stasis I-PHE
can O
be O
treated O
by O
the O
modified O
recipe O
. O

-DOCSTART- O


1 O
Containing O
potassium O
acetate O
and O
chloride O
which O
exert O
diuretic B-PHE
effect I-PHE
. O

2 O
. O
Orall O
adminstration O
of O
its O
decoction O
or O
infusion O
( O
2g/kg O
) O
can O
reduce O
vaccine-induced O
fever B-PHE
in O
rabbits O
. O

3 O
. O
Cardiotonic O
on O
the O
heart O
of O
frog O
weakened O
by O
quinine O
. O

Also O
causing O
constriction B-PHE
of I-PHE
blood I-PHE
vessels I-PHE
and O
rising O
of O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Different O
poisoning B-PHE
, O

-DOCSTART- O


abdominal B-PHE
pain I-PHE

-DOCSTART- O


five O
colored O
dysentery B-PHE
; O
dysentery B-PHE
with O
multi-colored O
stools O

-DOCSTART- O


a O
symptom B-PHE
of I-PHE
perspiration I-PHE
. O

-DOCSTART- O


affection O
by O
summer O
heat O
; O
exposure O
to O
summer O
heat O

-DOCSTART- O


Dalfopristin O
inhibits O
the O
early O
phase O
of O
protein B-PHE
synthesis I-PHE
by O
acting O
on O
bacterial O
ribosome O
. O

Quinupristin O
binds O
to O
a O
nearby O
site O
on O
the O
50S O
ribosomal O
subunit O
and O
prevents O
elongation O
of O
the O
polypeptide O
as O
well O
as O
causing O
incomplete O
chains O
to O
be O
released O
. O

-DOCSTART- O


Childhood B-PHE
T I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Polythiazide O
is O
a O
thiazide O
diuretic O
used O
to O
decrease O
edema B-PHE
and O
decrease O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Lymphocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
eliminate O
pus B-PHE
. O

-DOCSTART- O


Japanese O
herbal O
( O
Kampo O
) O
medicine O
, O
Hochuekkito O
( O
Bu-Zhong-Yi-Qi-Tang O
in O
Chinese O
, O
TJ-41 O
) O
and O
Juzentaihoto O
( O
Shi-Quan-Da-Bu-Tang O
in O
Chinese O
, O
TJ-48 O
) O
are O
well-known O
Kampo O
formulas O
used O
as O
tonic O
. O

Although O
these O
medicines O
have O
separately O
been O
applied O
to O
the O
patients O
clinically O
depending O
on O
their O
symptoms O
, O
the O
differences O
of O
the O
pharmacological O
activities O
for O
these O
medicines O
have O
not O
been O
fully O
understood O
. O

TJ-48 O
and O
TJ-41 O
were O
compared O
for O
their O
effects O
on O
antibody B-PHE
response I-PHE
in O
upper O
respiratory B-PHE
mucosal I-PHE
immune I-PHE
system I-PHE
in O
vivo O
. O

Oral O
administration O
of O
TJ-41 O
( O
100 O
mg O
kg(-1 O
) O
per O
day O
) O
to O
early O
aged O
BALB/c O
mice O
, O
which O
were O
nasally O
sensitized O
with O
influenza O
hemagglutinin O
vaccine O
, O
significantly O
enhanced O
influenza O
virus-specific O
IgA B-PHE
and I-PHE
IgG I-PHE
antibody I-PHE
titers O
in O
nasal O
cavity O
and O
sera O
, O
respectively O
. O

However O
, O
oral O
administration O
of O
TJ-48 O
( O
100 O
mg O
kg(-1 O
) O
per O
day O
) O
failed O
to O
show O
the O
enhancing O
activity O
. O

TJ-41 O
increased O
not O
only O
influenza O
virus-specific O
IgA B-PHE
antibody I-PHE
titer O
but O
also O
total O
IgA B-PHE
antibody I-PHE
titer O
in O
nasal O
cavity O
. O

The O
stimulating O
activity O
of O
TJ-41 O
disappeared O
after O
treatment O
with O
methotrexate O
. O

The O
present O
study O
strongly O
suggests O
that O
TJ-41 O
can O
stimulate O
the O
mucosal B-PHE
immune I-PHE
system I-PHE
of O
upper O
respiratory O
tract O
, O
and O
results O
in O
enhancement O
of O
antigen-specific B-PHE
antibody I-PHE
response I-PHE
in O
upper O
respiratory B-PHE
mucosal I-PHE
and O
systemic B-PHE
immune I-PHE
systems I-PHE
. O

-DOCSTART- O


To O
nourish O
blood B-PHE
, O
stanch O
bleeding B-PHE
, O
calm O
liver B-PHE
, O
moisten O
dryness B-PHE
. O

-DOCSTART- O


Thin B-PHE
Eyebrow I-PHE

-DOCSTART- O


Infant B-PHE
, I-PHE
Large I-PHE
for I-PHE
Gestational I-PHE
Age I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
chest O
, O
to O
eliminate O
the O
retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
, O
relieve O
vomiting B-PHE
. O

-DOCSTART- O


1 O
To O
moisurize O
the O
lung B-PHE
and O
relieve O
cough B-PHE
( O
lung-dryness B-PHE
with O
cough B-PHE
and O
hemoptysis B-PHE
) O
. O
2 O
To O
relieve O
cardiac B-PHE
heat I-PHE
and O
tranquilize O
the O
mind O
( O
convalescence O
of O
febrile B-PHE
diseases I-PHE
or O
yin-deficiency O
with O
heat B-PHE
manifested O
as O
irritability B-PHE
, O
insomnia B-PHE
, O
dreaminess B-PHE
, O
palpitation B-PHE
and O
absent-mindedness B-PHE
) O
. O

-DOCSTART- O


Svere O
nodular B-PHE
acne I-PHE

-DOCSTART- O


To O
remove O
toxic B-PHE
heat I-PHE
, O
to O
promote O
the O
drainage B-PHE
of I-PHE
pus I-PHE
, O
and O
to O
relieve O
dysuria B-PHE
. O

-DOCSTART- O


moisten O
skin B-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
a O
fever B-PHE
, O
shortness B-PHE
of I-PHE
breath I-PHE
, O
irritability B-PHE
and O
restlessness B-PHE
, O
mania B-PHE
derange I-PHE
due O
to O
blocked B-PHE
chest I-PHE
and O
diaphragm B-PHE
. O

It O
has O
a O
sever O
pain B-PHE
when O
pushing O
. O

-DOCSTART- O


anti-inflammatory B-PHE
effects O
of O
the O
Chinese O
herbal O
formula O
FAHF-2 O
in O
experimental O
and O
human O
IBD O
. O

-DOCSTART- O


To O
warm O
and O
replenish O
qi O
and O
blood B-PHE
. O

-DOCSTART- O


distension B-PHE
and O
pain B-PHE
of O
the O
breast O

-DOCSTART- O


This O
is O
a O
syndrome O
with O
a O
pain B-PHE
, I-PHE
bloat I-PHE
, I-PHE
and I-PHE
fullness I-PHE
in I-PHE
abdominal I-PHE
region I-PHE
. O

-DOCSTART- O


lumbago B-PHE
due O
to O
the O
kidney B-PHE
deficiency I-PHE

-DOCSTART- O


relieve O
stasis B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


de O
Novo O
Kidney O
Transplantation O

-DOCSTART- O


To O
eliminate O
phlegm B-PHE
, O
resuscitate O
, O
tranquilize O
, O
suppress O
wind B-PHE
and O
relieve O
convulsion B-PHE
. O

-DOCSTART- O


1 O
Its O
purgative O
effect O
is O
as O
three O
times O
as O
castor O
oil O
. O
2 O
. O

Its O
fresh O
preparation O
may O
inhibit O
the O
progress O
of O
acute B-PHE
lymphatic I-PHE
leukemia I-PHE
, O
acute O
and O
chronic B-PHE
granulocytic I-PHE
leukemia I-PHE
and O
acute B-PHE
monocytic I-PHE
leukemia I-PHE
. O

-DOCSTART- O


bleeding B-PHE
before O
defecation B-PHE

-DOCSTART- O


unblock O
blood B-PHE
vessel I-PHE

-DOCSTART- O


Wind-cold B-PHE
common O
cold B-PHE
, O
summerheat O
damage O
, O
vomiting B-PHE
diarrhea B-PHE
with O
abdominal B-PHE
pain I-PHE
, O
dribbling O
pain B-PHE
of I-PHE
urination I-PHE
, O
wind-damp B-PHE
impediment O
pain B-PHE
, O
cough B-PHE
and O
asthma B-PHE
, O
bronchial B-PHE
asthma I-PHE
. O

-DOCSTART- O


anhidrosis B-PHE
; O
adiaphoria B-PHE
; O
adiaphoresis B-PHE

-DOCSTART- O


Stage O
III O
Childhood B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
a O
pain B-PHE
under O
the O
side O
. O

-DOCSTART- O


tidal B-PHE
fever I-PHE
in O
the O
afternoon O

-DOCSTART- O


Eye B-PHE
health I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Eye B-PHE
, O
Diet B-PHE
cardiovascular I-PHE
disease I-PHE

-DOCSTART- O


Bleeding B-PHE
due O
to O
blood B-PHE
heat I-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
knocks O
and O
falls B-PHE
, O
impediment O
pain B-PHE
in O
joints O
. O

-DOCSTART- O


constipation B-PHE
and O
difficulty B-PHE
in I-PHE
urination I-PHE

-DOCSTART- O


To O
desolve O
stagnation B-PHE
; O

To O
stop O
bleeding B-PHE
; O

To O
modulate O
period O

-DOCSTART- O


Cold B-PHE
pain I-PHE
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-PHE
, O
cold O
mounting O
with O
abdominal B-PHE
pain I-PHE
, O
menstrual O
disorder O
. O

-DOCSTART- O


1 O
For O
cases O
of O
malaria B-PHE
with O
splenomegaly B-PHE
, O
epicgastric B-PHE
fullness I-PHE
, O
whitish B-PHE
fur I-PHE
on I-PHE
the I-PHE
tongue I-PHE
, O
wiry B-PHE
pulse I-PHE
, O
which O
are O
attributive O
to O
dysfunction B-PHE
of I-PHE
spleen I-PHE
and O
stagnation O
of O
vital O
energy O
and O
blood B-PHE
, O
omit O
Glycyrrhizae O
and O
add O
Ramulus O
cinnamoni O
, O
carapax O
trionycis O
to O
ac O

-DOCSTART- O


Recently O
, O
also O
used O
for O
biliary B-PHE
ascariasis I-PHE
, O
biliary B-PHE
infection I-PHE
and O
cholelithiasis B-PHE
with O
abdominal B-PHE
pain I-PHE
( O
adhesive O
ascarial O
and O
paralytic B-PHE
ileus I-PHE
) O
. O

-DOCSTART- O


Treatment O
of O
carbuncle O
, O
boil B-PHE
and O
other O
pyogenic B-PHE
infections I-PHE
of O
the O
skin O
, O
sore B-PHE
throat I-PHE
, O
scrofula B-PHE
, O
constipation B-PHE
. O

-DOCSTART- O


Tardive B-PHE
Dyskinesia I-PHE
. O

-DOCSTART- O


tonify O
the O
bladder B-PHE

-DOCSTART- O


tinea B-PHE

-DOCSTART- O


Haemostasis B-PHE

-DOCSTART- O


This O
is O
insanity B-PHE
caused O
by O
hurt O
of O
mind O
due O
to O
vexation B-PHE
and O
stuffiness B-PHE
. O

-DOCSTART- O


The O
previous O
experimental O
studies O
have O
demonstrated O
that O
addition O
of O
Huang O
Qi O
( O
[symbol O
: O
see O
text] O
Radix O
Astragali O
) O
to O
the O
formulated O
recipe O
Sheng O
Mai O
Yin O
( O
[symbol O
: O
see O
text] O
Decoction O
for O
Pulse-activation O
) O
exerts O
the O
effects O
of O
strengthening O
the O
myodynamia B-PHE
, O
increasing O
the O
coronary B-PHE
flow I-PHE
, O
improving O
myocardial B-PHE
metabolism I-PHE
, O
and O
resisting O
the O
arrhythmia B-PHE
. O

The O
active O
component O
of O
Huang O
Lian O
( O
[symbol O
: O
see O
text] O
Rhizoma O
Coptidis O
) O
can O
prolong O
the O
myocardial B-PHE
action I-PHE
potential O
and O
antagonize O
the O
chloroform- O
, O
aconitine- O
, O
barium O
chloride- O
, O
epinephrine- O
or O
coronary B-PHE
ligation-induced I-PHE
arrhythmia I-PHE
by O
blocking O
the O
calcium O
channel O
. O

Ku O
Shen O
( O
[symbol O
: O
see O
text] O
Radix O
Sophorae O
Flavescentis O
) O
contains O
matrine O
and O
flavones O
, O
which O
act O
as O
quinidine O
to O
decrease O
the O
excitability B-PHE
of I-PHE
the I-PHE
myocardium I-PHE
, O
prolong O
the O
refractory O
period O
, O
and O
inhibit O
the O
ectopic B-PHE
cardiac I-PHE
rhythm I-PHE
. O

And O
Dan O
Shen O
( O
[symbol O
: O
see O
text] O
Radix O
Salviae O
Miltiorrhizae O
) O
has O
the O
action O
of O
improving O
the O
ischemic B-PHE
state I-PHE
of O
the O
myocardium B-PHE
by O
dilating O
the O
coronary B-PHE
vessels I-PHE
. O

In O
conclusion O
, O
the O
definite O
therapeutic O
effects O
of O
Huang O
Lian O
Sheng O
Mai O
Yin O
in O
treating O
ventricular B-PHE
, I-PHE
atrial I-PHE
and I-PHE
nodal I-PHE
arrhythmia I-PHE
suggests O
that O
the O
prescription O
is O
rational O
and O
accords O
with O
the O
therapeutic O
principle O
of O
TCM O
. O

Except O
discomfort B-PHE
in O
the O
gastric B-PHE
cavity I-PHE
and O
poor O
appetite B-PHE
experienced O
by O
some O
patients O
, O
there O
is O
no B-PHE
toxic I-PHE
or O
adverse O
reaction O
. O

-DOCSTART- O


To O
relieve O
muscle B-PHE
; O
To O
clear O
heat B-PHE
, O
To O
accelerate O
rash B-PHE
, O
To O
stop O
cough B-PHE

-DOCSTART- O


clear O
heat B-PHE
and O
cool O
blood B-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
breast B-PHE
cancer I-PHE
, O
head B-PHE
and I-PHE
neck I-PHE
cancer I-PHE
, O
and O
lung B-PHE
cancer I-PHE
. O

-DOCSTART- O


1 O
To O
reduce O
heat B-PHE
caused O
by O
deficient O
yin O
; O
2 O
To O
clear O
heat B-PHE
in O
infants O
caused O
by O
malnutrition B-PHE

-DOCSTART- O


Tuberculosis B-PHE
, O
weak O
yin O
and O
agitated O
fire O
, O
thin B-PHE
and I-PHE
hot I-PHE
body I-PHE
, O
cough B-PHE
, O
phlegm B-PHE
, O
spitting B-PHE
blood I-PHE
, O
chest B-PHE
pain I-PHE
, O
dry B-PHE
mouth I-PHE
, O
frequent B-PHE
pulse I-PHE

-DOCSTART- O


dyspnea B-PHE
due O
to O
lung-heat B-PHE

-DOCSTART- O


Treatment O
of O
toothache B-PHE
due O
to O
caries B-PHE
, O
sores B-PHE
, O
ulcers B-PHE
, O
mastitis B-PHE
, O
scrofula B-PHE
, O
ringworm B-PHE
, O
tinea B-PHE
unguium I-PHE
. O

-DOCSTART- O


wind B-PHE
stroke I-PHE

apoplexy B-PHE

invasion B-PHE
of I-PHE
wind I-PHE
pathogen I-PHE

wind-stroke B-PHE
syndrome I-PHE
syndrome O
due O
to O
external O
affection O
by O
the O
pathogenic B-PHE
wind I-PHE
, O
manifested O
by O
fever B-PHE
, O
headache B-PHE
, O
perspiration B-PHE
, O
slow B-PHE
and I-PHE
floating I-PHE
pulse I-PHE
. O

-DOCSTART- O


Diabetes B-PHE
Mellitus I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE

-DOCSTART- O


Inhibiting O
the O
excessive O
secretion B-PHE
of I-PHE
bronchi I-PHE
and I-PHE
uterus I-PHE
. O

-DOCSTART- O


Qi O
vacuity O
, O
yin O
depletion O
and O
effulgent O
fire O
, O
cough B-PHE
and O
asthma B-PHE
with O
phlegm-blood B-PHE
, O
vacuity O
heat B-PHE
and O
vexation O
fatigue B-PHE
, O
diabetes B-PHE
mellitus I-PHE
due O
to O
internal O
heat B-PHE
, O
thirst B-PHE
with O
dry B-PHE
throat I-PHE
. O

-DOCSTART- O


For O
the O
treatment O
of O
bacterial B-PHE
infections I-PHE
. O

-DOCSTART- O


Known O
or O
Suspected O
Focal B-PHE
Liver I-PHE
Lesions I-PHE

-DOCSTART- O


clear O
heat B-PHE
and O
relieve O
toxicity B-PHE

-DOCSTART- O


join O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


stop O
tearing O

-DOCSTART- O


sores B-PHE
; O
boil B-PHE
suppurative I-PHE
infection I-PHE
on O
the O
body O
surface O
. O
including O
carbuncle B-PHE
, O
furuncle B-PHE
, O
deep-rooted O
carbuncle B-PHE
, O
multiple O
abscess B-PHE
, O
scrofula B-PHE
, O
ulcer B-PHE
. O

-DOCSTART- O


1 O
To O
dispel O
cold B-PHE
and O
stop O
pain B-PHE
; O
2 O
To O
regulate O
qi O
and O
harmonize O
the O
stomach B-PHE

-DOCSTART- O


Treatment O
of O
chronic B-PHE
rheumatiod I-PHE
arthritis I-PHE
with O
numbness B-PHE
and O
ankylosis B-PHE
, O
hemiplegia B-PHE
in O
stroke O
, O
convulsion B-PHE
, O
tetanus B-PHE
, O
leprosy B-PHE
, O
scabies B-PHE
, O
scrofula B-PHE
with O
suppuration B-PHE
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
disinhibit O
urine B-PHE
, O
relieve O
cough B-PHE
, O
stanch O
bleeding B-PHE
. O

-DOCSTART- O


To O
clear O
away O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
, O
relieve O
cough B-PHE
and O
eliminate O
phlegm B-PHE
. O

-DOCSTART- O


Untreated O
Childhood B-PHE
Myeloid I-PHE
Neoplasm I-PHE

-DOCSTART- O


sores B-PHE
of O
the O
mouth O
or O
tongue O
; O
aphthae B-PHE
and O
boil B-PHE
of O
mouth O
and O
tongue O

-DOCSTART- O


Treatment O
of O
dry B-PHE
cough I-PHE
caused O
by O
heat B-PHE
in O
the O
lung O
, O
bloody B-PHE
sputum I-PHE
in O
phthisis B-PHE
, O
thirst B-PHE
in O
febrile B-PHE
diseases I-PHE
. O

-DOCSTART- O


To O
suppress O
cough B-PHE
and O
calm O
asthma B-PHE
, O
dissipate O
stasis B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Lidocaine O
alters O
signal O
conduction O
in O
neurons B-PHE
by O
blocking O
the O
fast O
voltage B-PHE
gated I-PHE
sodium I-PHE
( I-PHE
Na+ I-PHE
) I-PHE
channels I-PHE
in O
the O
neuronal B-PHE
cell I-PHE
membrane I-PHE
that O
are O
responsible O
for O
signal O
propagation O
. O

Ceftriaxone O
works O
by O
inhibiting O
the O
mucopeptide B-PHE
synthesis I-PHE
and O
results O
in O
the O
formation O
of O
defective B-PHE
cell I-PHE
walls I-PHE
and O
cell B-PHE
death I-PHE
. O

-DOCSTART- O


flatulence B-PHE
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O

-DOCSTART- O


thirst B-PHE

-DOCSTART- O


105AD7 O
vaccine O
is O
a O
human O
anti-idiotype O
which O
mimics O
the O
antigen B-PHE
791Tgp72 I-PHE
. O

The O
mechanism O
of O
action O
of O
the O
vaccine O
has O
recently O
been O
clarified O
. O

The O
anti-idiotype O
is O
rapidly O
internalized O
on O
antigen B-PHE
presenting O
cells O
by O
Fc O
mediated O
endocytosis O
as O
both O
Fab O
and O
Ab O
complexed O
to O
alum O
are O
processed O
1000 O
fold O
less O
efficiently O
than O
whole O
Ab O
. O

Sequencing O
of O
the O
Ab O
have O
revealed O
that O
the O
CDR-H3 B-PHE
is O
hypermutated O
and O
contains O
HLA B-PHE
A1 I-PHE
, I-PHE
A3 I-PHE
and I-PHE
A24 I-PHE
, O
and O
HLA-DR1 B-PHE
, I-PHE
3 I-PHE
and I-PHE
7 I-PHE
MHC O
binding O
motifs O
. O

105AD7 O
is O
an O
antibody-based O
vaccine O
that O
mimics O
a O
target O
( O
CD55 B-PHE
) O
which O
is O
over-expressed O
in O
numerous O
cancers B-PHE
including O
those O
of O
the O
prostate B-PHE
, O
colon B-PHE
and O
pancreas B-PHE
. O

-DOCSTART- O


disperse O
glomus B-PHE

-DOCSTART- O


spontaneous B-PHE
sweating I-PHE
( O
perspiration B-PHE
) O
frequent B-PHE
sweating I-PHE
due O
to O
lowered B-PHE
superficial I-PHE
resistance I-PHE
brought O
on O
by O
deficiency O
of O
Gi O
. O

-DOCSTART- O


To O
warm O
the O
spleen B-PHE
and O
stomach B-PHE
, O
to O
regulate O
the O
adverse O
flow O
of O
the O
stomach O
qi O
, O
and O
to O
restore O
the O
kidney O
yang O
. O

-DOCSTART- O


warm O
the O
stomach B-PHE

-DOCSTART- O


hematuria B-PHE
; O
bloody B-PHE
urine I-PHE
without O
pain O

-DOCSTART- O


metrorrhagia B-PHE
and O
bloody B-PHE
stool I-PHE

-DOCSTART- O


invigorate O
the O
network B-PHE
vessels I-PHE

-DOCSTART- O


retention B-PHE
of I-PHE
the I-PHE
dead I-PHE
fetus I-PHE

-DOCSTART- O


Endocrine B-PHE
system I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Others O

-DOCSTART- O


phlegm B-PHE
syndrome I-PHE
induced O
by O
fright O

-DOCSTART- O


When O
administered O
, O
G17DT O
induces O
an O
immune B-PHE
response I-PHE
producing O
antibodies O
which O
bind O
with O
the O
peptide O
and O
also O
cross-react O
and O
neutralise O
gastrin B-PHE
17 I-PHE
thus O
inhibiting O
the O
growth B-PHE
of I-PHE
cancers I-PHE
and O
metastasis B-PHE
. O

In O
addition O
the O
product O
neutralizes O
glycine-extended B-PHE
gastrin I-PHE
17 I-PHE
which O
is O
also O
a O
stomach O
and O
pancreatic O
cancer O
growth O
factor O
. O

-DOCSTART- O


General O
Anesthetic O
Drug O
Adverse O
Reaction O

-DOCSTART- O


tetanus B-PHE

-DOCSTART- O


Venous B-PHE
Insufficiency I-PHE

-DOCSTART- O


To O
drain O
the O
pus B-PHE
, O
eradicate O
toxicity B-PHE
, O
eliminate O
the O
dead B-PHE
tissue I-PHE
and O
promote O
the O
growth B-PHE
of I-PHE
new I-PHE
tissue I-PHE
. O

-DOCSTART- O


For O
clearing O
heat B-PHE
and O
removing O
toxic B-PHE
substances I-PHE

-DOCSTART- O


eliminate O
melasma B-PHE

-DOCSTART- O


A O
symptom O
that O
a O
person O
has O
tightness B-PHE
in I-PHE
the I-PHE
chest I-PHE
and O
does O
not O
feel O
hungry O
. O

-DOCSTART- O


To O
remove O
phlegm B-PHE
, O
disperse O
the O
lumps B-PHE
, O
detoxify O
and O
relieve O
swelling B-PHE
. O

-DOCSTART- O


G4544 O
reduces O
bone B-PHE
loss I-PHE
by O
inhibiting O
calcium B-PHE
resorption I-PHE
from I-PHE
bone I-PHE
. O

Preclinical O
evidence O
suggests O
that O
the O
mechanism O
of O
G4544 O
action O
is O
multifactorial O
and O
different O
from O
other O
current O
therapies O
used O
to O
treat O
bone B-PHE
loss I-PHE
, O
such O
as O
estrogen B-PHE
or O
selective O
estrogen O
receptor O
modulators O
( O
SERMs O
) O
, O
calcitonin O
, O
or O
bisphosphonates O
( O
e.g O
. O
, O
Zometa O
or O
Fosamax O
) O
. O

G4544 O
preferentially O
accumulates O
in O
metabolically O
active O
regions O
of O
bone O
, O
inhibits O
osteoclast-mediated B-PHE
bone I-PHE
resorption I-PHE
, O
and O
favorably O
alters O
bone B-PHE
mineral I-PHE
composition I-PHE
and O
properties O
. O

-DOCSTART- O


T'aeyang B-PHE
meridian I-PHE
affected O
by O
the O
wind B-PHE
; O

invasion B-PHE
of I-PHE
wind I-PHE
pathogen I-PHE
in O
T'aeyang O
meridian O

-DOCSTART- O


the O
four O
limbs O
are O
swollen B-PHE
and O
they O
feel O
painful O

-DOCSTART- O


constipation B-PHE
; O
suffer B-PHE
from I-PHE
constipation I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Others O
, O
Overall O
CVD O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Body B-PHE
weight I-PHE
, O
Evacuation B-PHE
, O
Hemostatic B-PHE
function I-PHE
. O

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
Overactive I-PHE

-DOCSTART- O


Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


Diarrhea B-PHE
, O
dysentery B-PHE
, O
leprosy B-PHE
, O
scrotal B-PHE
wind I-PHE
, O
itchy B-PHE
skin I-PHE
. O

-DOCSTART- O


tonify O
marrow B-PHE

-DOCSTART- O


rhIGFBP-3 O
is O
a O
protein O
that O
is O
normally O
found O
in O
our O
bloodstream O
that O
has O
been O
shown O
to O
induce O
cancer O
cell O
death O
in O
a O
variety O
of O
experimental O
systems O
. O

Several O
studies O
have O
demonstrated O
that O
cancer B-PHE
risk O
increases O
with O
decreasing O
levels O
of O
circulating O
IGFBP-3 B-PHE
. O

IGFBP-3 B-PHE
can O
induce O
cell B-PHE
cycle I-PHE
arrest I-PHE
and O
enhance O
the O
efficacy O
of O
chemotherapeutic O
agents O
. O

-DOCSTART- O


pain B-PHE
of O
back O
and O
vertebra O

-DOCSTART- O


Dragon's O
blood O
( O
Xuejie O
) O
is O
used O
with O
Frankincense O
( O
Ruxiang O
) O
and O
Myrrh O
( O
Moyao O
) O
in O
the O
formula O
Qili O
San O
. O

-DOCSTART- O


stagnation O
of O
milk O
without O
secretion O
after O
delivery O
. O

-DOCSTART- O


critical B-PHE
symptom I-PHE
complex I-PHE
with O
complicated O
, O
changable O
and O
serious O
conditions O
; O

disease B-PHE
due O
to O
the O
poisonous B-PHE

-DOCSTART- O


Treatment O
of O
menstrual B-PHE
disorders I-PHE
, O
anemia B-PHE
, O
numbness B-PHE
and O
paralysis B-PHE
, O
rheumatic B-PHE
arthralgia I-PHE
. O

-DOCSTART- O


To O
tonify O
the O
spleen B-PHE
, O
to O
relieve O
diarrhea B-PHE
, O
to O
replenish O
the O
kidney B-PHE
, O
to O
arrest O
seminal B-PHE
emission I-PHE
, O
and O
to O
nourish O
the O
heart B-PHE
, O
to O
induce O
tranquillization B-PHE
. O

-DOCSTART- O


clear O
heat B-PHE
and O
moisten O
the O
lung B-PHE

-DOCSTART- O


Acute O
Gout B-PHE
Flare O

-DOCSTART- O


To O
open O
orifices O
and O
arouse O
spirit O
, O
break O
phlegm B-PHE
and O
repel O
foulness O
, O
move O
qi O
and O
quicken O
blood B-PHE
, O
relieve O
pain B-PHE
. O

-DOCSTART- O


This O
is O
a O
symptom O
with O
bleeding B-PHE
in O
the O
gum O
and O
root O
of O
tooth O
that O
comes O
out O
of O
the O
gums O
caused O
by O
a O
crack B-PHE
of I-PHE
the I-PHE
gum I-PHE
. O

-DOCSTART- O


Adult B-PHE
T I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


GSK716155 O
, O
a O
GLP-1 O
receptor O
agonist O
, O
has O
been O
shown O
to O
have O
multiple O
physiologic O
activities O
in O
the O
central O
nervous O
system O
and O
gastrointestinal O
system O
that O
could O
lower O
A1C O
. O

It O
increases O
peripheral B-PHE
glucose I-PHE
uptake I-PHE
, O
enhances O
insulin B-PHE
secretion I-PHE
, O
decreases O
glucagon B-PHE
secretion I-PHE
, O
delays O
gastric B-PHE
emptying I-PHE
, O
reduces O
food O
intake O
and O
induces O
satiety B-PHE
at O
CNS O
. O

-DOCSTART- O


( O
1 O
) O
pain B-PHE
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O
( O
2 O
) O
upper B-PHE
abdominal I-PHE
pain I-PHE

-DOCSTART- O


This O
is O
passing B-PHE
urine I-PHE
unconsciously I-PHE
. O

-DOCSTART- O


Pain B-PHE

-DOCSTART- O


tinnitus B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
poor B-PHE
appetite I-PHE
, O
vomiting B-PHE
, O
and O
diarrhea B-PHE
due O
to O
various O
reasons O
. O

-DOCSTART- O


warm O
the O
kidney B-PHE
and O
support O
Yang O

-DOCSTART- O


Multiple B-PHE
Myeloma I-PHE
and O
Plasma B-PHE
Cell I-PHE
Neoplasm I-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Blood B-PHE
pressure I-PHE
, O
Lipid B-PHE
profile I-PHE
, O
Overall O
CVD B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE

-DOCSTART- O


warm O
the O
kidney B-PHE

-DOCSTART- O


retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
; O
dyspepsia B-PHE
retention O
of O
food O
resulting O
from O
dysfunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE

-DOCSTART- O


Treatment O
of O
impotence B-PHE
, O
seminal B-PHE
emission I-PHE
, O
enuresis B-PHE
, O
frequent B-PHE
urination I-PHE
, O
aching B-PHE
of I-PHE
the I-PHE
loins I-PHE
and I-PHE
knees I-PHE
with O
cold B-PHE
sensation O
, O
asthma B-PHE
in O
deficiency B-PHE
syndromes I-PHE
of O
the O
kidney O
, O
diarrhea B-PHE
occurring O
before O
dawn O
daily O
. O

-DOCSTART- O


Strength B-PHE
and O
power B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Liver B-PHE
, O
Lipid O
profile O
, O
Quality O
of O
life O
, O
absorption B-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Overall O
CVD O
, O
Liver B-PHE
health I-PHE
, O
Diet B-PHE
related B-PHE
cardiovascular I-PHE
disease I-PHE
, O
Inflammation B-PHE
, O
Other B-PHE
system I-PHE
health I-PHE
, O
Others O
, O
Neurological B-PHE
systems I-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
motility B-PHE

-DOCSTART- O


Lower O
the O
level B-PHE
of I-PHE
serum I-PHE
cholesterol I-PHE
and O
( O
B)-lipoprotein O
in O
experimental O
animals O
with O
hyperlipidemia. B-PHE
. O

-DOCSTART- O


Nepafenac O
is O
a O
prodrug O
. O

After O
penetrating O
the O
cornea O
, O
nepafenac O
undergoes O
rapid O
bioactivation O
to O
amfenac O
, O
which O
is O
a O
potent O
NSAID O
that O
uniformly O
inhibits O
the O
COX1 B-PHE
and I-PHE
COX2 I-PHE
activity I-PHE
. O

-DOCSTART- O


Thyroid B-PHE
tumor I-PHE
, O
lump B-PHE
in O
neck O
, O
slight B-PHE
yellow I-PHE
tong I-PHE
, O
heavy B-PHE
pulse I-PHE

-DOCSTART- O


scrofula B-PHE
; O
tuberculosis B-PHE
of I-PHE
the I-PHE
cervical I-PHE
lymphic I-PHE
node I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Eye B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Quality O
of O
life O
, O
Eye B-PHE
health I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
General O
woman O
, O
General B-PHE
skin I-PHE
health I-PHE
, O
Others O
, O
Protective B-PHE
immunity I-PHE
, O
Intelligence B-PHE
, O
Endurance B-PHE

-DOCSTART- O


To O
remove O
heat B-PHE
, O
to O
promote O
the O
production O
of O
body B-PHE
fluid I-PHE
, O
and O
to O
facilitate O
the O
drainage O
of O
pus O
and O
the O
subsidence O
of O
swelling B-PHE
. O

-DOCSTART- O


Hypogonadotropic B-PHE
Hypogonadism I-PHE

-DOCSTART- O


forceful O
pulse O

-DOCSTART- O


Esophageal B-PHE
Bleeding I-PHE

-DOCSTART- O


For O
nutritional O
supplementation O
, O
also O
for O
treating O
dietary B-PHE
shortage I-PHE
or I-PHE
imbalance I-PHE
. O

-DOCSTART- O


nourish O
the O
liver B-PHE
and O
kidney B-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Motivation O
, O
Mood O
, O
Endocrine B-PHE
system I-PHE
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


relieve O
toxicity B-PHE

-DOCSTART- O


phlegm-retention B-PHE
syndrome I-PHE
; O
congested B-PHE
fluids I-PHE
; O
retention B-PHE
of I-PHE
phlegm I-PHE
and O
fluid O
( O
1 O
) O
morbid B-PHE
conditions I-PHE
characterized O
by O
accumulation O
of O
dampness O
as O
a O
pathological O
product O
resulting O
from O
dysfunction B-PHE
of I-PHE
the I-PHE
lung I-PHE
, O
spleen B-PHE
md O
kidney B-PHE
or O
from O
disturbance B-PHE
of I-PHE
water I-PHE
circulation I-PHE
in O
the O
passage O
of O
Triple O
Ch'o O
. O

The O
thicker O
dampness B-PHE
is O
called O
phlegm O
, O
while O
the O
thinner O
fluid O
. O

Retention B-PHE
of I-PHE
phlegm I-PHE
and O
fluid O
can O
give O
rise O
to O
various O
diseases B-PHE
, O
one O
of O
the O
four O
kinds O
of O
fluid B-PHE
retention I-PHE
. O

( O
2 O
) O
a O
morbid B-PHE
condition I-PHE
due O
to O
fluid B-PHE
retention I-PHE
in O
the O
stomach O
and O
intestines O
. O

-DOCSTART- O


restrain O
Aconiti B-PHE
Tuber I-PHE

-DOCSTART- O


To O
tonify O
the O
kidney B-PHE

-DOCSTART- O


Lidocaine O
alters O
signal O
conduction O
in O
neurons O
by O
blocking O
the O
fast O
voltage O
gated O
sodium O
( O
Na+ O
) O
channels O
in O
the O
neuronal O
cell O
membrane O
that O
are O
responsible O
for O
signal O
propagation O
. O

-DOCSTART- O


Treatment O
of O
lung B-PHE
abscess I-PHE
with O
purulent B-PHE
expectoration I-PHE
, O
heat B-PHE
in I-PHE
the I-PHE
lung I-PHE
with O
cough B-PHE
and O
dyspnea B-PHE
, O
acute B-PHE
dysentery I-PHE
, O
acute B-PHE
urinary I-PHE
infection I-PHE
, O
carbuncles B-PHE
and O
sores B-PHE
. O

-DOCSTART- O


redness B-PHE
, I-PHE
swelling I-PHE
and I-PHE
pain I-PHE
of I-PHE
the I-PHE
eyes I-PHE

-DOCSTART- O


Persistent B-PHE
Asthma I-PHE

-DOCSTART- O


invigorate O
blood B-PHE
and O
move O
stasis B-PHE

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
cancer/tumors B-PHE
( O
unspecified O
) O
, O
lung B-PHE
cancer I-PHE
, O
myelodysplastic B-PHE
syndrome I-PHE
, O
and O
prostate B-PHE
cancer I-PHE
. O

-DOCSTART- O


Treatment O
of O
stagnancy B-PHE
of I-PHE
undigested I-PHE
food I-PHE
with O
abdominal B-PHE
distension I-PHE
and O
constipation B-PHE
, O
weakness B-PHE
and O
edema B-PHE
of O
the O
legs O
with O
oliguria B-PHE
. O

-DOCSTART- O


1 O
For O
cases O
of O
metrorrhagia B-PHE
attributive O
to O
failure O
of O
the O
spleen B-PHE
to O
control O
blood B-PHE
, O
subtract O
Aucklandiae O
and O
polygalae O
and O
add O
Fructus O
Corni O
to O
nourish O
liver B-PHE
and O
stop O
metrorrhagia B-PHE
. O

2 O
For O
cases O
with O
bloody B-PHE
stools I-PHE
attributive O
to O
hypofunction B-PHE
of I-PHE
spleen I-PHE
with O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Monocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


Treament O
of O
vertigo B-PHE
, O
tinnitus B-PHE
, O
weakness B-PHE
in I-PHE
the I-PHE
loins I-PHE
and I-PHE
knees I-PHE
, O
premature B-PHE
whitening I-PHE
of I-PHE
hair I-PHE
and O
impaired B-PHE
eyesight I-PHE
due O
to O
deficiency O
of O
yin O
of O
the O
liver O
and O
kidney O
. O

-DOCSTART- O


For O
cases O
of O
collapse O
due O
to O
massive O
hemorrhage B-PHE
manifested O
as O
cold B-PHE
limbs I-PHE
, O
oily B-PHE
sweat I-PHE
, O
pale B-PHE
complexion I-PHE
, O
spiritlessness B-PHE
, O
small B-PHE
and I-PHE
indistinct I-PHE
pulse I-PHE
, O
use O
high O
grade O
of O
Radix O
Ginseng O
( O
such O
as O
Ginseng O
Korea O
or O
Ginseng O
Jilin O
) O
instead O
of O
Codonopsis O
Pilosulae O
. O

-DOCSTART- O


1 O
Treatment O
of O
skin B-PHE
infection I-PHE
, O
sorethroat B-PHE
, O
erysipelas B-PHE
, O
appendicitis B-PHE
, O
etc O
. O
Recently O
also O
used O
for O
leptospirosis B-PHE
. O

2 O
Treatment O
of O
conjunctivitis B-PHE
. O
Recently O
used O
for O
acute O
and O
chronic B-PHE
conjunctivitis I-PHE
, O
trachoma B-PHE
, O
keratitis B-PHE
, O
corneal B-PHE
ulcer I-PHE
, O
etc O
. O
, O
orally O
or O
toptically O
. O
diarrhea B-PHE
and O
dysentery B-PHE
of O
dampness-heat B-PHE
type O
, O
skin B-PHE
lesions I-PHE
of O
dampness B-PHE
type O
, O
etc O
. O

-DOCSTART- O


break O
hard B-PHE
mass I-PHE
and O
dissipate O
accumulation B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
absorption B-PHE
, O
Digestion B-PHE
, O
motility B-PHE
, O
Others O
, O
General O
woman O

-DOCSTART- O


sores B-PHE
with O
swelling B-PHE

-DOCSTART- O


arthralgia B-PHE
; O
Pi B-PHE
syndrome I-PHE

-DOCSTART- O


Type B-PHE
2 I-PHE
Diabetes I-PHE
Mellitus I-PHE
. O

-DOCSTART- O


Major B-PHE
Depressive I-PHE
Disorder I-PHE

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
fibromyalgia B-PHE
. O

-DOCSTART- O


warm O
the O
bladder B-PHE

-DOCSTART- O


Benign B-PHE
Prostatic I-PHE
Hyperplasia I-PHE

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
Urinary B-PHE
systems I-PHE

-DOCSTART- O


blood-heat B-PHE

-DOCSTART- O


The O
primary O
activity O
of O
insulin O
is O
the O
regulation O
of O
glucose B-PHE
metabolism I-PHE
. O

Insulin O
promotes O
glucose O
and O
amino O
acid O
uptake O
into O
muscle O
and O
adipose O
tissues O
, O
and O
other O
tissues O
except O
brain O
and O
liver O
. O

It O
also O
has O
an O
anabolic O
role O
in O
stimulating O
glycogen B-PHE
, I-PHE
fatty I-PHE
acid I-PHE
, I-PHE
and I-PHE
protein I-PHE
synthesis I-PHE
. O

Insulin O
inhibits O
gluconeogenesis B-PHE
in O
the O
liver O
. O

Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity I-PHE
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin B-PHE
receptor I-PHE
substrates I-PHE
( O
IRS B-PHE
) O
proteins O
, O
Cbl B-PHE
, O
APS B-PHE
, O
Shc B-PHE
and O
Gab B-PHE

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-PHE
of I-PHE
downstream I-PHE
signaling I-PHE
molecules I-PHE
including O
PI3 B-PHE
kinase I-PHE
and O
Akt B-PHE
. O

Akt O
regulates O
the O
activity B-PHE
of I-PHE
glucose I-PHE
transporter I-PHE
4 I-PHE
( O
GLUT4 B-PHE
) O
and O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
which O
play O
a O
critical O
role O
in O
metabolism B-PHE
and O
catabolism B-PHE
. O

-DOCSTART- O


Infection B-PHE
of O
upper O
respiratory O
tract O
, O
pneumonia B-PHE
, O
acute B-PHE
gastroenteritis I-PHE
, O
dysentery B-PHE
, O
sore B-PHE
and O
boil B-PHE
, O
scab B-PHE
and O
lichen B-PHE
, O
eczema B-PHE
, O
burns B-PHE
and O
scalds B-PHE
, O
infection B-PHE
of O
biliary O
tract O
, O
poisonous B-PHE
insect I-PHE
stings I-PHE
. O

-DOCSTART- O


Heat B-PHE
bind O
and O
accumulation O
, O
constipation B-PHE
w O
ith O
abdominal B-PHE
pain I-PHE
, O
edema B-PHE
distention I-PHE
fullness I-PHE
. O

-DOCSTART- O


vomiting B-PHE
and O
diarrhea B-PHE

-DOCSTART- O


Clarithromycin O
also O
inhibits O
the O
hepatic O
microsomal O
CYP3A4 O
isoenzyme O
and O
P-glycoprotein O
, O
an O
energy-dependent O
drug O
efflux O
pump O
. O

-DOCSTART- O


Untreated O
Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE

-DOCSTART- O


Treatment O
of O
sore B-PHE
throat I-PHE
and O
hoarseness B-PHE
of I-PHE
voice I-PHE
, O
cough B-PHE
with O
yellow B-PHE
sticky I-PHE
sputum I-PHE
, O
dysuria B-PHE
, O
external O
use O
for O
pemphigus B-PHE
and O
eczema B-PHE
. O

-DOCSTART- O


Wind-damp B-PHE
impediment I-PHE
pain I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
pain B-PHE
in O
stomach O
duct O
, O
hemiplegia B-PHE
, O
gan B-PHE
accumulation I-PHE
, O
dysentery B-PHE
. O

-DOCSTART- O


Effect O
of O
Hachimijiogan O
( O
HJ O
) O
on O
dopamine B-PHE
( O
DA B-PHE
) O
, O
serotonin B-PHE
( O
5-HT B-PHE
) O
and O
vasoactive B-PHE
intestinal I-PHE
peptide I-PHE
( O
VIP B-PHE
) O
was O
examined O
in O
plasma O
and O
hypothalamic O
tissue O
of O
sulpiride-induced O
hyperprolactinemic O
rats O
( O
SHR O
) O
. O

Similar O
to O
bromocriptine B-PHE
( O
BR B-PHE
) O
, O
HJ O
, O
in O
combination O
with O
sulpiride O
, O
suppressed O
plasma B-PHE
prolactin I-PHE
levels I-PHE
raised O
by O
sulpiride O
alone O
. O

Furthermore O
, O
HJ O
, O
together O
with O
sulpiride O
, O
increased O
plasma B-PHE
DA I-PHE
levels I-PHE
decreased O
by O
sulpiride O
alone O
, O
while O
5-HT B-PHE
in O
plasma O
was O
increased O
by O
sulpiride O
and O
HJ O
, O
individually O
or O
in O
combination O
. O

However O
, O
plasma B-PHE
VIP I-PHE
levels I-PHE
were O
under O
detection O
limits O
on O
some O
occasions O
after O
HJ O
treatment O
. O

Successively O
, O
DA B-PHE
, I-PHE
5-HT I-PHE
and I-PHE
VIP I-PHE
levels I-PHE
in O
the O
hypothalamus O
were O
determined O
. O

Similar O
to O
the O
effect O
caused O
by O
BR B-PHE
, I-PHE
DA I-PHE
and I-PHE
5-HT I-PHE
levels I-PHE
in O
hypothalamic O
tissue O
reduced O
by O
sulpiride O
alone O
were O
also O
significantly O
increased O
by O
HJ O
together O
with O
sulpiride O
, O
while O
VIP B-PHE
levels I-PHE
were O
sometimes O
under O
detection O
levels O
with O
or O
without O
HJ O
. O

These O
results O
suggest O
that O
HJ O
stimulates O
the O
hypothalamus B-PHE
to O
increase O
DA B-PHE
and O
5-HT B-PHE
in O
SHR O
, O
providing O
evidence O
for O
the O
clinical O
efficiency O
of O
HJ O
in O
combating O
hyperprolactinemia B-PHE
. O

The O
effect O
of O
HJ O
on O
VIP B-PHE
in O
plasma O
or O
hypothalamic O
tissue O
is O
, O
however O
, O
questionable O
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Quality O
of O
life O
, O
Endocrine B-PHE
system I-PHE
, O
Motivation O
, O
Endurance B-PHE
, O
Memory B-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Liver B-PHE
health I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Liver B-PHE
, O
Others O
, O
Respiratory B-PHE
systems I-PHE
, O
effort O
, O
Respiratory B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
disinhibit O
damp B-PHE
, O
cool O
blood B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Oxamniquine O
may O
associate O
with O
an O
irreversible O
inhibition O
of O
the O
nucleic B-PHE
acid I-PHE
metabolism I-PHE
of I-PHE
the I-PHE
parasites I-PHE
. O

A O
hypothesis O
has O
been O
put O
forth O
that O
the O
drug O
is O
activated O
by O
a O
single O
step O
, O
in O
which O
a O
schistosome O
sulfotransferase O
enzyme O
converts O
oxamniquine O
into O
an O
ester O
( O
probably O
acetate O
, O
phosphate O
, O
or O
sulfate O
) O
. O

Subsequently O
, O
the O
ester O
spontaneously O
dissociates O
, O
the O
resulting O
electrophilic O
reactant O
is O
capable O
of O
alkylation O
of O
schistosome O
DNA O
. O

-DOCSTART- O


breast B-PHE
abscess I-PHE
; O
acute B-PHE
mastitis I-PHE

-DOCSTART- O


move O
Gi O
( O
Qi O
) O
and O
break O
blood B-PHE

-DOCSTART- O


Prostate B-PHE
cancer I-PHE

-DOCSTART- O


Simvastatin O
competitively O
inhibits O
HMG-CoA O
reductase O
, O
lowers O
plasma O
cholesterol O
and O
lipoprotein O
levels O
, O
and O
modulates O
immune B-PHE
responses I-PHE
by O
suppressing O
MHC O
II O
on O
interferon O
gamma-stimulated O
, O
antigen-presenting B-PHE
cells I-PHE
such O
as O
human B-PHE
vascular I-PHE
endothelial I-PHE
cells I-PHE
. O

Sitagliptin O
is O
a O
highly O
selective O
DPP-4 O
inhibitor O
, O
and O
increases O
insulin B-PHE
release I-PHE
and O
decreases O
glucagon B-PHE
levels I-PHE
in O
the O
circulation O
in O
a O
glucose-dependent O
manner O
. O

-DOCSTART- O


Rivanicline O
is O
a O
( O
E)-metanicotine O
hemigalactarate O
. O

It O
effectively O
inhibits O
TNF- O
and O
LPS-induced O
IL-8 B-PHE
production O
in O
different O
cell O
types O
. O

-DOCSTART- O


Paclitaxel O
interferes O
with O
the O
normal O
function B-PHE
of I-PHE
microtubule I-PHE
growth I-PHE
. O

Whereas O
drugs O
like O
colchicine O
cause O
the O
depolymerization B-PHE
of I-PHE
microtubules I-PHE
in O
vivo O
, O
paclitaxel O
arrests O
their O
function O
by O
having O
the O
opposite O
effect O
; O

it O
hyper-stabilizes O
their O
structure O
. O

This O
destroys O
the O
cell's O
ability O
to O
use O
its O
cytoskeleton B-PHE
in O
a O
flexible O
manner O
. O

Specifically O
, O
paclitaxel O
binds O
to O
the O
; O

subunit B-PHE
of I-PHE
tubulin I-PHE
. O

Tubulin O
is O
the O
building O
block O
of O
mictotubules O
, O
and O
the O
binding O
of O
paclitaxel B-PHE
locks O
these O
building O
blocks O
in O
place O
. O

The O
resulting O
microtubule B-PHE
/ I-PHE
paclitaxel I-PHE
complex I-PHE
does O
not O
have O
the O
ability O
to O
disassemble O
. O

This O
adversely O
affects O
cell O
function O
because O
the O
shortening O
and O
lengthening O
of O
microtubules B-PHE
( O
termed O
dynamic O
instability O
) O
is O
necessary O
for O
their O
function O
as O
a O
transportation O
highway O
for O
the O
cell O
. O

Chromosomes B-PHE
, O
for O
example O
, O
rely O
upon O
this O
property O
of O
microtubules B-PHE
during O
mitosis O
. O

Further O
research O
has O
indicated O
that O
paclitaxel O
induces O
programmed O
cell B-PHE
death I-PHE
( I-PHE
apoptosis I-PHE
) I-PHE
in I-PHE
cancer I-PHE
cells I-PHE
by O
binding O
to O
an O
apoptosis B-PHE
stopping O
protein O
called O
Bcl-2 O
( O
B-cell O
leukemia O
2 O
) O
and O
thus O
arresting O
its O
function O
. O

-DOCSTART- O


Breast B-PHE
Cancer I-PHE

-DOCSTART- O


Bipolar B-PHE
Disorder I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Mood O
, O
Quality O
of O
life O
, O
absorption O
, O
motility B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


Recurrent O
Adult B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
the O
water O
extract O
of O
Samultang O
( O
SMT O
) O
, O
a O
Chinese O
herb O
, O
on O
apoptotic B-PHE
cell I-PHE
death I-PHE
by O
H(2)O(2)-induced O
oxidative B-PHE
stress I-PHE
in O
SK-N-MC O
cells O
. O

A O
nuclear O
fragmentation O
was O
observed O
via O
fluorescence O
imaging O
12 O
h O
after O
exposure O
to O
30 O
microM O
H(2)O(2 O
) O
and O
DNA O
laddering O
was O
detected O
via O
agarose O
electrophoresis O
gel O
. O

In O
addition O
, O
increases O
in O
sub-G1 O
phase O
and O
cleavage O
of O
the O
PARP O
protein O
were O
observed O
. O

However O
, O
treatment O
with O
SMT O
for O
2 O
h O
prior O
to O
H(2)O(2 O
) O
exposure O
significantly O
reduced O
apoptotic B-PHE
cell I-PHE
death I-PHE
induced O
by O
incubation O
with O
30 O
microM O
H(2)O(2 O
) O
in O
SK-N-MC O
cells O
. O

Pre-incubation O
with O
water O
extract O
of O
SMT O
for O
2 O
h O
prevented O
the O
H(2)O(2)-induced O
decrease O
in O
mitochondrial O
transmembrane O
potential O
. O

SMT O
also O
attenuated O
the O
increase O
in O
caspase-3 B-PHE
activity I-PHE
and O
the O
breakdown O
of O
PARP B-PHE
protein I-PHE
caused O
by O
H(2)O(2)-induced O
oxidative O
stress O
. O

These O
results O
suggest O
that O
the O
water O
extract O
of O
SMT O
provides O
inhibition O
of O
apoptotic B-PHE
cell I-PHE
death I-PHE
against O
oxidative B-PHE
injury I-PHE
in O
SK-N-MC O
cells O
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
t(9;11)(p22;q23 O
) O
; O
MLLT3-MLL O

-DOCSTART- O


Wind-damp B-PHE
impediment I-PHE
pain I-PHE
, O
pain B-PHE
from O
arthritis B-PHE
, O
painful O
swelling B-PHE
from O
knocks O
and O
falls O
, O
amenorrhea B-PHE
, O
dysmenorrhea B-PHE
, O
swollen B-PHE
welling I-PHE
abscess I-PHE
, O
erysipelas B-PHE
, O
goose-foot B-PHE
wind I-PHE
, O
snake B-PHE
or I-PHE
insect I-PHE
bites I-PHE
. O

-DOCSTART- O


weakness B-PHE
of I-PHE
constitution I-PHE

-DOCSTART- O


Treatment O
of O
cough B-PHE
in O
colds O
with O
retention O
of O
phlegm B-PHE
marked O
by O
dyspnea B-PHE
, O
profuse O
expectoration B-PHE
and O
feeling O
of O
stuffiness B-PHE
in O
the O
chest O
, O
external O
use O
for O
pyogenic B-PHE
infections I-PHE
of O
the O
skin O
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption O
, O
Lipid O
profile O
, O
Liver B-PHE
health I-PHE
, O
DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
motility O
, O
Liver B-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


To O
warm O
the O
spleen B-PHE
, O
stop O
vomiting B-PHE
, O
clear O
away O
summer-heat B-PHE
and O
eliminate O
dampness B-PHE
. O

-DOCSTART- O


Immune B-PHE
Thrombocytopenic I-PHE
Purpura I-PHE

-DOCSTART- O


In O
the O
process O
of O
binding O
, O
the O
receptor O
is O
actually O
activated O
- O
causing O
a O
process O
known O
as O
depolarization B-PHE
. O

-DOCSTART- O


1 O
Its O
decoction O
is O
a O
broad-spectrum O
bacteriostatic O
. O

2 O
Stimulating O
the O
mucosa O
of O
respiratory O
tract O
directly O
, O
promoting O
secretion O
and O
expectoration O
. O

3 O
Its O
volatile O
oil O
kills O
trichomonas B-PHE
vaginalis I-PHE
in O
vitro O
. O

4 O
Its O
volatile O
oil O
is O
also O
an O
analgesic O
. O

-DOCSTART- O


cool O
blood B-PHE
and O
relieve O
toxicity B-PHE

-DOCSTART- O


coldness B-PHE
and O
pain B-PHE
in O
the O
lumbar O
and O
knee O
region O

-DOCSTART- O


High-Grade O
Lymphoma B-PHE

-DOCSTART- O


To O
boost O
essence O
, O
brighten O
eyes B-PHE
, O
cool O
blood B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Stroke B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
. O

-DOCSTART- O


Ephedrine O
is O
a O
sympathomimetic O
amine O
- O
that O
is O
, O
its O
principal O
mechanism O
of O
action O
relies O
on O
its O
direct O
and O
indirect O
actions O
on O
the O
adrenergic B-PHE
receptor I-PHE
system I-PHE
, O
which O
is O
part O
of O
the O
sympathetic B-PHE
nervous I-PHE
system I-PHE
. O

Ephedrine O
increases O
post-synaptic O
noradrenergic O
receptor O
activity O
by O
( O
weakly O
) O
directly O
activating O
post-synaptic O
receptors O
and O
receptors O
, O
but O
the O
bulk O
of O
its O
effect O
comes O
from O
the O
pre-synaptic B-PHE
neuron I-PHE
being O
unable O
to O
distinguish O
between O
real O
adrenaline B-PHE
or O
noradrenaline B-PHE
from O
ephedrine O
. O

The O
ephedrine O
, O
mixed O
with O
noradrenaline B-PHE
, O
is O
transported O
through O
the O
noradrenaline B-PHE
reuptake I-PHE
complex I-PHE
and O
packaged O
( O
along O
with O
real O
noradrenaline B-PHE
) O
into O
vesicles B-PHE
that O
reside O
at O
the O
terminal O
button O
of O
a O
nerve B-PHE
cell I-PHE
. O

Ephedrine's O
action O
as O
an O
agonist O
at O
most O
major O
noradrenaline O
receptors O
and O
its O
ability O
to O
increase O
the O
release O
of O
both O
dopamine B-PHE
and O
to O
a O
lesser O
extent O
, O
serotonin B-PHE
by O
the O
same O
mechanism O
is O
presumed O
to O
have O
a O
major O
role O
in O
its O
mechanism O
of O
action O
. O

-DOCSTART- O


Allogeneic O
Haplo-Stem O
Cell O
Transplatation O
( O
SCT O
) O

-DOCSTART- O


relieve O
cough B-PHE
and O
dispel O
phlegm B-PHE

-DOCSTART- O


It O
usually O
happens O
by O
the O
liver B-PHE
heat I-PHE
, O
lung B-PHE
heat I-PHE
, O
heart B-PHE
heat I-PHE
, O
insufficiency O
of O
the O
genuine O
Eum O
, O
or O
infiltration O
of O
pathogenic O
wind O
to O
the O
ocular O
connection O
. O

Usually O
disease B-PHE
can O
be O
divided O
by O
the O
coloration O
. O

-DOCSTART- O


Progestins B-PHE
diffuse O
freely O
into O
target O
cells O
and O
bind O
to O
the O
progesterone O
receptor O
. O

Once O
bound O
to O
the O
receptor O
, O
progestins B-PHE
slow O
the O
frequency O
of O
release O
of O
gonadotropin B-PHE
releasing I-PHE
hormone I-PHE
( O
GnRH B-PHE
) O
from O
the O
hypothalamus O
and O
blunt O
the O
pre-ovulatory O
LH B-PHE
surge O
. O

Ethinyl O
estradiol O
is O
a O
synthetic O
derivative O
of O
the O
natural O
estrogen B-PHE
estradiol I-PHE
. O

Estrogens B-PHE
increase O
the O
hepatic B-PHE
synthesis I-PHE
of I-PHE
sex I-PHE
hormone I-PHE
binding I-PHE
globulin I-PHE
, O
thyroid-binding B-PHE
globulin I-PHE
, O
and O
other O
serum B-PHE
proteins I-PHE
and O
suppress O
follicle-stimulating B-PHE
hormone I-PHE
from O
the O
anterior O
pituitary O
. O

-DOCSTART- O


Childhood B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE
With O
t(9;22)(q34;q11.2 O
) O
; O
BCR-ABL1 O

-DOCSTART- O


Neoplasms B-PHE
, I-PHE
Hormone-Dependent I-PHE

-DOCSTART- O


dispel O
wind B-PHE
and O
drain O
dampness B-PHE

-DOCSTART- O


nasal B-PHE
obstruction I-PHE
and O
the O
deep B-PHE
and I-PHE
harsh I-PHE
voice I-PHE

-DOCSTART- O


loss B-PHE
of I-PHE
appetite I-PHE

-DOCSTART- O


blood B-PHE
vacuity I-PHE
, O
septicemia B-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
numbness B-PHE
and O
paralysis B-PHE
, O
aching B-PHE
in O
lumbus O
and O
legs O
. O

-DOCSTART- O


To O
drain O
the O
pus B-PHE
and O
relieve O
swelling B-PHE
( O
external O
use O
for O
various O
kinds O
of O
severe O
skin B-PHE
lesions I-PHE
; O
oral O
use O
of O
Crotonis O
fried O
yellow O
wax O
for O
bone B-PHE
tuberculosis I-PHE
and O
osteomyelitis B-PHE
) O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
remove O
obstruction B-PHE
from O
the O
channels O
and O
to O
remove O
heat B-PHE
from O
blood B-PHE
and O
cause O
subsidence O
of O
swelling B-PHE
. O

-DOCSTART- O


Rescinnamine O
Binds O
to O
and O
inhibits O
the O
angiotensin B-PHE
converting I-PHE
enzyme I-PHE
. O

Rescinnamine O
competes O
with O
angiotensin O
I O
for O
binding O
at O
the O
angiotensin-converting B-PHE
enzyme I-PHE
, O
blocking O
the O
conversion O
of O
angiotensin B-PHE
I I-PHE
to O
angiotensin B-PHE
II I-PHE
. O

Inhibition O
of O
ACE O
results O
in O
decreased O
plasma B-PHE
angiotensin I-PHE
II I-PHE
. O

As O
angiotensin B-PHE
II I-PHE
is I-PHE
a O
vasoconstrictor B-PHE
and O
a O
negative-feedback O
mediator O
for O
renin B-PHE
activity O
, O
lower O
concentrations O
result O
in O
a O
decrease O
in O
blood B-PHE
pressure I-PHE
and O
stimulation O
of O
baroreceptor O
reflex O
mechanisms O
, O
which O
leads O
to O
decreased O
vasopressor B-PHE
activity O
and O
to O
decreased O
aldosterone B-PHE
secretion O
. O

-DOCSTART- O


Liver B-PHE
Cirrhosis I-PHE

-DOCSTART- O


fetal B-PHE
leakage I-PHE

-DOCSTART- O


relax O
tension B-PHE

-DOCSTART- O


invigorate O
blood B-PHE

-DOCSTART- O


BACKGROUND O
: O
The O
diagnosis O
of O
encephalitis B-PHE
is O
usually O
presumptive O
based O
on O
MRI O
, O
cerebrospinal O
fluid O
analysis O
, O
or O
both O
. O

A O
definitive O
diagnosis O
based O
on O
histopathology O
, O
however O
, O
is O
required O
for O
optimizing O
treatment O
strategies O
. O

OBJECTIVE O
: O
To O
investigate O
the O
diagnostic O
yield O
and O
adverse O
effects O
of O
minimally O
invasive O
brain O
biopsies O
in O
dogs O
with O
encephalitis B-PHE
. O

ANIMALS O
: O
Seventeen O
dogs O
with O
suspected O
encephalitis B-PHE
, O
based O
on O
MR O
imaging O
and O
cerebrospinal O
fluid O
analysis O
. O

METHODS O
: O
Retrospective O
study O
. O

Minimally O
invasive O
, O
free-hand O
brain O
biopsy O
specimens O
were O
taken O
from O
forebrain O
lesions O
through O
a O
4-mm O
burr O
hole O
using O
a O
Sedan O
side-cutting O
needle O
. O

Routine O
histopathological O
examination O
was O
performed O
. O

The O
adverse O
effects O
were O
assessed O
by O
MRI O
evaluations O
after O
biopsy O
procedure O
( O
12 17 O
) O
and O
by O
sequential O
neurological O
examinations O
. O

RESULTS O
: O
The O
overall O
diagnostic O
yield O
with O
regard O
to O
a O
specific O
type O
of O
encephalitis B-PHE
was O
0.82 O
. O

Encephalitis B-PHE
was O
evident O
in O
an O
additional O
0.12 O
, O
but O
a O
specific O
disease B-PHE
could O
not O
be O
determined O
. O

There O
were O
no O
deaths O
caused O
by O
the O
biopsy O
procedure O
itself O
, O
but O
the O
indirect O
case O
fatality O
rate O
was O
0.06 O
. O

Morbidity O
was O
0.29 O
, O
including O
stupor B-PHE
, O
seizures B-PHE
, O
tetraparesis B-PHE
, O
hemiparesis B-PHE
, O
ataxia B-PHE
, O
and O
loss B-PHE
of I-PHE
conscious I-PHE
proprioception I-PHE
. O

All O
these O
signs O
resolved O
within O
03 14 O
days O
. O

CONCLUSIONS O
AND O
CLINICAL O
IMPORTANCE O
: O
Minimally O
invasive O
brain O
biopsy O
in O
dogs O
with O
suspected O
encephalitis B-PHE
leads O
to O
a O
definite O
diagnosis O
in O
the O
majority O
of O
dogs O
, O
allowing O
for O
a O
specific O
treatment O
. O

The O
advantages O
of O
a O
definite O
diagnosis O
outweigh O
potential O
case O
fatality O
rate O
and O
temporary O
neurological B-PHE
deficits I-PHE
. O

-DOCSTART- O


paralysis B-PHE
due O
to O
stroke B-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
B I-PHE
Virus I-PHE

-DOCSTART- O


Vaginal B-PHE
Diseases I-PHE

-DOCSTART- O


Clindamycin O
inhibits O
bacterial B-PHE
protein I-PHE
synthesis I-PHE
by O
binding O
to O
bacterial O
50S O
ribosomal O
subunits O
. O

-DOCSTART- O


This O
is O
a O
syndrome O
with O
throat B-PHE
pain I-PHE
due O
to O
Wind-Heat B-PHE
. O

It O
has O
red B-PHE
spots I-PHE
on O
all O
of O
the O
body O
, O
burning B-PHE
heat I-PHE
, O
difficulty B-PHE
in I-PHE
swallowing I-PHE
foods I-PHE
, O
headache B-PHE
, O
and O
aversion B-PHE
to O
cold O
. O

-DOCSTART- O


Encainide O
is O
a O
sodium O
channel O
blocker O
, O
binding O
to O
voltage B-PHE
gated I-PHE
sodium I-PHE
channels I-PHE
. O

It O
stabilizes O
the O
neuronal B-PHE
membrane I-PHE
by O
inhibiting O
the O
ionic B-PHE
fluxes I-PHE
required O
for O
the O
initiation O
and O
conduction O
of O
impulses O
. O

Ventricular O
excitability O
is O
depressed O
and O
the O
stimulation O
threshold O
of O
the O
ventricle B-PHE
is O
increased O
during O
diastole O
. O

-DOCSTART- O


Loratadine O
is O
a O
second-generation O
H1 O
histamine O
antagonist O
drug O
and O
appears O
to O
suppress O
the O
release B-PHE
of I-PHE
histamine I-PHE
and I-PHE
leukotrienes I-PHE
from O
mast O
cells O
, O
and O
the O
release B-PHE
of I-PHE
leukotrienes I-PHE
from O
human O
lung O
fragments O
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Mimmuietabolic B-PHE
rate I-PHE
/ I-PHE
energy I-PHE
expenditure I-PHE

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
Endocrine O
& O
reproductive B-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Others O
, O
Man O

-DOCSTART- O


Tetracycline O
passively O
diffuses O
through O
porin B-PHE
channels I-PHE
in O
the O
bacterial O
membrane O
and O
reversibly O
binds O
to O
the O
30S B-PHE
ribosomal I-PHE
subunit I-PHE
, O
preventing O
binding O
of O
tRNA B-PHE
to O
the O
mRNA-ribosome B-PHE
complex I-PHE
, O
and O
thus O
interfering O
with O
protein B-PHE
synthesis I-PHE
. O

The O
reduced O
metronidazole O
then O
covalently O
binds O
to O
DNA B-PHE
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial B-PHE
nucleic I-PHE
acid I-PHE
synthesis I-PHE
and O
resulting O
in O
bacterial B-PHE
cell I-PHE
death I-PHE
. O

Esomeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-PHE
acid I-PHE
secretion I-PHE
by O
specific O
inhibition O
of O
the O
H<sup>+</sup>/K<sup>+</sup>-ATPase O
in O
the O
gastric O
parietal O
cell O
. O

-DOCSTART- O


swelling B-PHE
and O
pain B-PHE
due O
to O
trauma B-PHE

-DOCSTART- O


gases B-PHE
retention I-PHE
in O
the O
lungs O

-DOCSTART- O


Prednisolone O
can O
inhibit O
leukocyte B-PHE
infiltration I-PHE
at O
the O
site O
of O
inflammation O
, O
interfere O
with O
mediators B-PHE
of I-PHE
inflammatory I-PHE
response I-PHE
, O
and O
suppress O
humoral B-PHE
immune I-PHE
responses I-PHE
. O

-DOCSTART- O


Hepatitis B-PHE
C I-PHE
Recurrence I-PHE
After O
Liver O
Transplant O

-DOCSTART- O


promote O
liquid O

-DOCSTART- O


To O
cool O
lung B-PHE
, O
release O
discomfort B-PHE
in O
pharynx O
, O
remove O
epidemic B-PHE
evils I-PHE
, O
and O
to O
relieve O
cough B-PHE
. O

-DOCSTART- O


Cisplatin O
binds O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA O
, O
inducing O
intrastrand B-PHE
and I-PHE
interstrand I-PHE
DNA I-PHE
cross-links I-PHE
, O
as O
well O
as O
DNA-protein B-PHE
cross-links I-PHE
. O

-DOCSTART- O


epistaxis B-PHE
; O
nosebleed B-PHE

-DOCSTART- O


edema B-PHE
, O
pathogenesis O
of O
which O
is O
associated O
with O
dysfunction B-PHE
of I-PHE
the I-PHE
lung I-PHE
, I-PHE
spleen I-PHE
and I-PHE
kidney I-PHE
. O

-DOCSTART- O


Hip B-PHE
Fracture I-PHE

-DOCSTART- O


Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Woman O
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


general O
edema B-PHE
with O
abdominal B-PHE
distension I-PHE
of O
body O
and O
extremities O

-DOCSTART- O


To O
eliminate O
blood B-PHE
stasis I-PHE
with O
strong O
effect O
, O
promote O
the O
flow O
of O
qi O
, O
remove O
the O
retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
, O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Postpartum B-PHE
Sexual I-PHE
Function I-PHE

-DOCSTART- O


Fluoxetine O
is O
an O
antidepressant O
belonging O
to O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
class O
, O
and O
blocks O
the O
reuptake B-PHE
of I-PHE
serotonin I-PHE
at O
the O
serotonin O
reuptake O
pump O
of O
the O
neuronal O
membrane O
, O
enhancing O
the O
actions B-PHE
of I-PHE
serotonin I-PHE
on O
5HT<sub>1A</sub> O
autoreceptors O
. O

Venlafaxine O
and O
its O
active O
metabolite O
, O
O-desmethylvenlafaxine O
( O
ODV O
) O
, O
inhibit O
the O
reuptake B-PHE
of I-PHE
both I-PHE
serotonin I-PHE
and I-PHE
norepinephrine I-PHE
with O
a O
potency O
greater O
for O
the O
5-HT O
than O
for O
the O
NE O
reuptake O
process O
. O

Quetiapine's O
antipsychotic O
activity O
is O
likely O
due O
to O
a O
combination O
of O
antagonism B-PHE
at O
D2 O
receptors O
in O
the O
mesolimbic O
pathway O
and O
5HT2A O
receptors O
in O
the O
frontal O
cortex O
. O

-DOCSTART- O


To O
strengthen O
the O
spleen B-PHE
. O

-DOCSTART- O


Treament O
of O
cough B-PHE
, O
sore B-PHE
throat I-PHE
and O
hoarseness B-PHE
of I-PHE
voice I-PHE
due O
to O
heat B-PHE
in O
the O
lung O
, O
epigastic B-PHE
pain I-PHE
due O
to O
stagnation B-PHE
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O


fracture B-PHE

-DOCSTART- O


1 O
L-tetrahydropalmatine O
20-40mg/kg O
intraperitoneally O
in O
mice O
and O
15mg/kg O
intravenously O
in O
rabbits O
exert O
analgesic O
and O
sedative O
effects O
. O

2 O
Reducing O
the O
body O
temperature O
in O
healthy O
or O
thyroidectomized O
rats O
. O

-DOCSTART- O


